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ABSTRACT 
 The U.S. population is currently undergoing a major demographic transition, with 
increasing racial and ethnic diversity of the older adult population. As the growing 
population of older adults advances in age, memory complaints are projected to increase 
in prevalence particularly among African Americans and present a challenge to clinicians 
who must differentiate between normal aging and progressive neurocognitive conditions 
(Celsis, 2000; Sherwin, 2000). As targeted therapeutic interventions and emerging 
therapies for AD are much more likely to be effective in the earlier stages of the disease 
(Loewenstein, Curiel, Duara & Buschke, 2017), early assessment and detection of AD, 
especially in groups more likely to develop the disorder, such as African Americans, has 
become increasingly important. As such, the current study examined the performance of 
African Americans, both cognitively normal and those with amnestic-mild cognitive 
impairment (aMCI), on a novel cognitive stress test, the Loewenstein-Acevedo Scale of 
Semantic Interference and Learning (LASSI-L) and found that those with aMCI exhibit 
more impairment in their initial learning and storage of information and suffer from 
proactive semantic interference due to their inability to inhibit responses. Additionally, 
this study found that the LASSI-L serves as a better predictor of diagnostic group 
classification compared to traditional neuropsychological measures. Taken together these 




cognitive impairment among African American older adults, which will hopefully guide 













































Chapter 1: Introduction 
 
 
 The U.S. population is currently undergoing a major demographic transition, with 
increasing racial and ethnic diversity of the older adult population. Over the next several 
decades one in every five Americans will be age 65 or older and by 2050, the proportion 
of minorities will far outnumber non-Hispanic whites (U.S. Census Bureau, 2017). As the 
growing population of older adults advances in age, memory complaints are projected to 
increase in prevalence and present a challenge to clinicians who must differentiate 
between normal aging and progressive neurocognitive conditions, such as Alzheimer’s 
disease (Celsis, 2000; Sherwin, 2000). Alzheimer’s disease (AD), the most prevalent 
neurocognitive disorder, is highest among African Americans who are 64% more likely 
to develop AD when compared to Caucasians (Steenland, Goldstein, Levey, & Wharton, 
2016). Despite this higher prevalence, AD in African Americans has gone largely 
understudied. Increased understanding of AD in African Americans, specifically 
regarding measures that effectively provide early detections can provide important 
insights regarding the characteristics of observed memory deficits as well as which of 
characteristics is more predictive of AD brain pathology and further progression to full 
AD.  Given the paucity of research in the area, this dissertation study examines effective 
early detection of Alzheimer’s disease in African Americans.  
Alzheimer’s Disease 
 Alzheimer’s Disease (AD) is a progressive degenerative disease of the brain, 
beginning in middle age or later life, which is characterized by progressive cognitive 
decline and brain pathology (Logie, Parra, & Della Sala, 2015; Saykin and Rabin, 2014). 




focused on the presence of the deposition of amyloid-beta (AE) peptide (plaques) and 
intraneuronal fibrils composed of abnormal tau proteins (tangles) (Hyman et al., 2012).  
The typical presentation of AD includes an insidious onset, memory impairment, and a 
gradually progressive course evolving to include declines in other cognitive functions as 
well as personality, emotion, and functional abilities (Saykin & Rabin, 2014). Currently, 
a diagnosis of Alzheimer’s dementia is based on meeting the criteria outlined in the 
following three classification systems: 1) Diagnostic Statistical Manual of Mental 
Disorders, 5th edition (DSM-5; refer to Appendix A), 2) the International Classification 
of Diseases, 10th edition (ICD-10; refer to Appendix B), or 3) the National Institute of 
Neurological and Communicative Disorders and Stroke (NINCDS) of the United States 
and the Alzheimer’s Disease and Related Disorders Association (ADRDA) (NINCDS-
ADRDA; refer to Appendix C).  
 AD was first described in 1906 by German psychiatrist and neuropathologist, 
Alois Alzheimer (Zilka & Novak, 2006; Cipriani, Dociotti, Picchi, & Conuccelli, 2011). 
Dr. Alzheimer, whose initial work largely focused on correlating psychiatric symptoms to 
pathology of the nervous system, examined a woman by the name of Auguste Deter who 
was suffering from memory loss, disorientation, depression, and hallucinations (Zilka & 
Novak, 2006; Cipriani, Dociotti, Picchi, & Conuccelli, 2011). After her death at age 55, 
Dr. Alzheimer examined Auguste’s brain using the newly developed Bielschowsky’s 
silver staining method and described what he saw: “in the center of an otherwise almost 
normal cell, there stands out one or several fibrils due to their characteristic thickness and 
peculiar impregnability. Numerous small military foci are found in the superior layers. 




all, we have to face a peculiar disease” (as cited by Cipriani, Dociotti, Picchi, & 
Conuccelli, 2011, p. 277; Alzheimer, 1907). These observations made by Dr. Alzheimer 
would be later recognized today as the plaques and tangles characteristic in the brains of 
patients with the disease. Dr. Alzheimer continued to study patients similar to Auguste 
and the disease was later termed “Alzheimer’s disease” by Dr. Emil Kraepelin, 
Alzheimer’s mentor, in the 8th edition of his Handbook of Psychiatry (Cipriani, Dociotti, 
Picchi, & Conuccelli, 2011; Kraepelin, 1910).  
 Research investigating AD has continued in the hundred years since it was first 
described by Dr. Alzheimer. Today two variants of AD are recognized: sporadic and 
familial (Schoenberg & Duff, 2011). Sporadic AD, which accounts for over 95% of 
cases, develops after the age of 65 and follows a slow and insidious course which lasts 
roughly 10 years (Saykin & Rabin, 2014; Schoenberg & Duff, 2011). Sporadic AD is 
associated with the APOE gene, of which there are three alleles: epsilon 2, 3, and 4 
(Saykin and Rabin, 2014). Because over 60% of AD patients are homozygous for APOE 
ε4, this allele is considered a risk factor for the development of AD (Saykin & Rabin, 
2014). The familial variant of AD occurs before the age of 65 and follows a more rapid 
progression (Schoenberg & Duff, 2011). The familial variant is associated with mutations 
in three genes (APP, PSEN1, PSEN2) resulting in autosomal dominant AD by 
upregulating the production of amyloid beta protein (Saykin & Rabin, 2014). While other 
genome studies have investigated additional genes associated with AD, none has proven 








The AD Continuum 
 
Historically, AD was synonymous with the later dementing stage of disease, 
however recent technological advances have allowed us to examine more closely the 
changes in the brain that occur early in the disease (Sperling et al., 2011). Over the last 
decade, research has demonstrated that biological changes characteristic of AD (i.e. 
plaques and tangles) can be detected through cerebral spinal fluid (CSF) and imaging (i.e. 
MRI and PET amyloid scans) decades prior to the stage of dementia (Sperling, Mormino, 
& Johnson, 2014). As a result, AD is now conceptualized as a continuum, ranging from 
individuals at risk for further decline (i.e. evidencing biological correlates of AD) to the 
later dementing stage of the disease (Dubois et al., 2016). Based on these biological 
correlates (i.e. plaques and tangles), researchers have determined that AD occurs in three 
phases: the preclinical stage, mild cognitive impairment (MCI), and dementia (Sperling et 
al., 2011). Although exact transitional periods are difficult to determine, and likely 
involve some overlap (Sperling et al., 2011), understanding the different phases of AD is 
important in that it allows for the diagnostic accuracy of patient presentation as well as 
the identification of potentially optimal opportunities to employ treatments and emerging 
therapies. In order to provide clarity, the following sections will review the three stages 
of AD.  
 Preclinical AD.  The preclinical stage of AD represents a new addition to the AD 
disease model (Dubois et al., 2016). Individuals identified as being in the preclinical 
stage are those who evidence biomarkers which are signature of the disease, namely AE 
and tau depositions, but whose cognitive functioning is normal on objective 




serve as biomarkers for the identification of the disease and can be identified by 
laboratory tests such as Positron Emission Tomography (PET) amyloid imaging or by 
assessing the ratios of AE and tau present in cerebrospinal fluid (CSF) (Loewenstein et 
al., 2012). Other biomarkers used include the identification of medial temporal atrophy 
on magnetic resonance imaging (MRI), regional hypometabolism on PET scans, 
abnormal functional MRI activation patterns, and the presence of an Apolipoprotein H4 
genotype (Loewenstein et al., 2012; Sperling et al., 2011).  
 As previously mentioned, individuals in the preclinical stage of AD evidence 
normal cognitive functioning on objective neuropsychological measures. Despite this, 
these individuals often report subjective cognitive decline (SCD) or “perceived decline in 
memory and/or other cognitive abilities relative to their previous level of performance, in 
the absence of objective neuropsychological deficits” (Rabin, Smart, & Amariglio, 2017; 
Jessen et al., 2014). Several studies have demonstrated the association between SCD and 
the accumulation of AE, finding that increased reports of subjective memory concerns are 
associated with increased AE and neuritic plaque burden (Sperling, Mormino, & Johnson, 
2014; Rabin, Smart, & Amariglio, 2017; Amariglio et al., 2012; Perrotin et al., 2012; 
Harten et al., 2013; Kryscio et al., 2014). These findings suggest that SCD may be an 
indicator of preclinical AD and that individuals with SCD may be at increased risk for 
future pathological decline (Rabin, Smart, & Amariglio, 2017).  
 Multiple longitudinal studies have demonstrated high progression rates of 
preclinical AD to later stages of the disease. These studies have consistently 
demonstrated that individuals who evidence increased AE deposits are more likely to 




Mormino et al., 2014; Lim et al., 2014; Landau et al., 2012). While individuals with 
abnormal biomarkers do not always progress to MCI, studies have found that progression 
rates are highest in those with subjective memory difficulties not significant enough to 
warrant a diagnosis of MCI (38.9%) and those with AE and an additional biomarker such 
as elevated tau (32.7%) (Vos et al., 2013; Loewenstein et al., 2012). Of note, research on 
preclinical AD progression rates has largely failed to examine racial disparities, 
particularly in African Americans. As a result, little is known about how progression 
rates in African Americans may compare to those of other racial groups. A thorough 
literature review only identified one study conducted by Chen et al. (2017) examining the 
progression from normal cognition to mild cognitive impairment (MCI) in a diverse 
sample. This study investigated progression rates among Whites (N= 92), African 
Americans (N=78), and Hispanics (N= 84) from both clinic (N=13) and community (N= 
241) samples over a 7-year period. Results from this study found progression rates for 
clinic samples to be 30% per year, whereas the conversion rate for the community sample 
was 5% per year (Chen et al., 2017). Hispanics had the highest progression rates with no 
significant difference observed between the progression rates of Whites and African 
Americans (Chen et al., 2017). Consistent with previous research, older age and SCD 
were risk factors for progressing from normal cognition to MCI (Chen et al., 2017). 
While this study examined racial differences in progression rates from normal cognition 
to MCI, more research is needed to examine factors that may influence progression rates 
in racially and ethnically diverse populations.  
 Mild Cognitive Impairment. Individuals who progress from a normal level of 




has been termed “mild cognitive impairment” (MCI) (Albert et al., 2011; Petersen, 2004) 
and represents the stage of cognitive impairment seen between those with normal 
cognition and those with dementia (Petersen et al., 1999). In 2011, the National Institute 
on Aging- Alzheimer’s Association (NIA-AA) developed core clinical criteria for the 
diagnosis of MCI to be utilized by healthcare providers without access to advanced 
imaging techniques or cerebrospinal fluid analysis (Albert et al., 2011). According to 
these criteria a diagnosis of MCI is made when there is a) concern regarding a change in 
cognition b) impairment in one or more cognitive domains c) preservation of 
independence in functional abilities and d) no evidence of dementia (Albert et al., 2011).  
 In order to make a diagnosis of MCI there first should “be evidence of concern 
about a change in cognition, in comparison with the person’s previous level” (Albert et 
al., 2011, p.271). This concern regarding a change in cognition “can be obtained from the 
patient, from an informant who knows the patient well, or from a skilled clinician 
observing the patient” (Albert et al., 2011, p. 271). Once it has been established that there 
is concern regarding a change in cognition, formal cognitive testing should be conducted 
to determine if there is impairment in one or more cognitive domains (i.e. memory, 
executive functioning, attention, language, and visuospatial skills1) (Albert et al., 2011). 
Individuals with memory impairment, more specifically in episodic memory (i.e. the 
ability to learn and retain new information) most commonly progress from MCI to AD 
dementia (Albert et al., 2011).  Impairment is characterized as “lower performance in one 
or more cognitive domains that is greater than would be expected for the patient’s age 
                                                 
1 For more information regarding cognitive domains interested readers are referred to 




and educational background” which is demonstrated by test scores 1 to 1.5 standard 
deviations below what would be expected for age and education matched peers (Albert et 
al., 2011, p. 271). If the patient is tested repeatedly, a decline in performance should be 
evident over time (Albert et al., 2011).  
 If it has been determined than an individual has impairment in one or more 
cognitive domains, their level of independence and functional abilities should be assessed 
to establish that functioning is not so severely impaired that a diagnosis of dementia is 
warranted (Albert et al., 2011). Those with MCI should demonstrate a preservation of 
independence in functional abilities such as preparing meals, paying bills, and shopping 
(Albert et al., 2011). While patients may demonstrate mild problems completing these 
tasks (i.e., taking more time to complete a task, being less efficient, making more errors) 
they should be able to complete these tasks with minimal aids or assistance (Albert et al., 
2011). Lastly, it is important to note that those with MCI should not meet criteria for 
dementia as “these cognitive changes should be sufficiently mild that there is no evidence 
of a significant impairment in social or occupational functioning” (Albert et al., 2011, p. 
272).  
 Individuals in the MCI phase of AD are considered at risk for further decline to 
AD dementia (Petersen, 2011). Longitudinal studies have shown that the rate of 
conversion from MCI to dementia over a three-year period ranges from 20% to 53% 
(Black, 1999; Mckelvey et al., 1999; Wolf et al., 1998) and 100% conversion to AD 
dementia is seen during a 9.5-year period (Morris et al., 2001). Progression rates for 
African Americans are largely understudied as the vast majority of research includes 




by racial group (Gao et al., 2014). However, a recent study investigating MCI 
progression in African Americans found an annual progression rate of 5.9%, which is 
comparable to rates found in Caucasian samples (Gao et al., 2014). While progression 
rates are largely understudied in diverse populations, research suggests that the greatest 
risk factors for progressing to AD dementia is the presence of memory deficits and 
multiple AD biomarkers (Vos et al., 2013; Loewenstein et al., 2012).  
 AD Dementia. During the last stage of AD, individuals progress to a state of 
dementia which is a “clinical syndrome characterized by a loss of previously acquired 
cognitive functions that adversely affects an individual’s ability to complete day to day 
activities” (Schoenberg & Duff, 2011, p.357).  According to the NIA-AA, the diagnosis 
of AD dementia is made when there are cognitive or behavioral symptoms that: a) 
interfere with the ability to function at work or at usual activities; b) represent a decline 
from previous levels of functioning and performing; and c) are not explained by delirium 
or major psychiatric disorder (McKhann et al., 2011). Cognitive impairment due to 
dementia can be “detected and diagnosed through a combination of (1) history taking 
from the patient and a knowledgeable informant and (2) an objective cognitive 
assessment, either a “bedside” mental status examination or neuropsychological testing” 
(McKhann et al., 2011, p. 265). This cognitive impairment involves a minimum of two of 
the following domains (i.e. memory, reasoning or judgement, visuospatial abilities, 
language functions, changes in personality or behavior) (McKhann et al., 2011). AD 
dementia involves an insidious onset with symptoms gradually presenting over months to 
years (McKhann et al., 2011). As mentioned previously, those with AD dementia 




initial and most prominent cognitive deficits follow either an Amnestic or Nonamnestic 
presentation (McKhann et al., 2011). The Amnestic presentation of AD dementia is the 
most common and includes impairments in learning and recall of newly learning 
information (McKhann et al., 2011). While memory is the primary deficit, those with an 
Amnestic presentation must also evidence deficits in at least one other cognitive domain 
such as attention, executive functioning, visuospatial functioning, or language (McKhann 
et al., 2011). Nonamnestic presentations of AD dementia are less common and involve 
primary deficits in language, visuospatial, or executive functioning2 as opposed to 
memory (McKhann et al., 2011).  
 Prevalence studies indicate that the rate of AD dementia in the U.S. is estimated 
to be least 4.7 million (Herbert, Weuve, Scherr, & Evans, 2013; Alzheimer’s Association, 
2017). Furthermore, studies indicate that the risk of developing AD seems to be highest 
among African Americans who are 64% more likely to develop AD when compared to 
Caucasian Americans (Steenland, Goldstein, Levey & Wharton, 2016). Several studies 
have examined the incidence and prevalence of AD dementia by race (Hebert et al., 2010; 
Tang et al., 2001; Katz et al., 2012; Kukull et al., 2002; Fitzpatrick et al., 2004; 
Plassmann et al., 2011) including a meta-analysis conducted by Steenland et al. (2016), 
which found that the estimated AD prevalence rates for those ages 65-90 years to be 
5.5% for Whites and 8.6% for African Americans. Similar results were observed in a 
review conducted by Mehta and Yeo (2017) who examined the prevalence and incidence 
rates of all types of dementia diagnosis among different racial and ethnic groups and 
                                                 
2 Expanded information regarding AD deficits in language, visuospatial and executive 




found higher dementia prevalence rates for African Americans, ranging from 7.2% to 
20.9%, with an average annual incidence rate of 2.6%. Taken together, the higher 
incidence and prevalence of AD dementia rates in African Americans likely reflects a 
combination of biological, psychological, and socioeconomic factors.  
Symptoms of AD 
 
Given that AD is the most prevalent of the dementia syndromes, identifying 
contributing signs and symptoms of the disease has become increasingly important. 
Research has identified several neuropathological signs, neuropsychological symptoms, 
and neurocognitive symptoms characteristic of AD (Schoenberg & Duff, 2011).  
 Neuropathology of AD. Since AD was first described by Dr. Alois Alzheimer in 
1906, research has continued to investigate the neuropathology of the disease (Zilka & 
Novak, 2006; Cipriani, Dociotti, Picchi, & Conuccelli, 2011). Definitive diagnosis of AD 
can only be made at autopsy because the brain of an individual with AD does not show 
any gross anatomical alterations that can be identified diagnostically. Thus, a histological 
examination must be conducted to observe microscopic evidence of the disease (Perl, 
2010). There are three pathognomonic changes which can be detected in the brain of 
someone with AD: amyloid-beta (AE) peptide deposits or “plaques”, neurofibrillary 
“tangles” composed of tau proteins, and brain atrophy (Raskin, Cummings, Hardy, 
Schuh, & Dean, 2015). Other changes that occur include “synaptic loss, neuronal loss, 
gliosis, degenerative changes in white matter, granulovacuolar degeneration, cerebral 
amyloid angiopathy, and other protein aggregates” (Raskin, Cummings, Hardy, Schuh, & 
Dean, 2015).  




and is based on the discovery that the amyloid precursor protein (APP) gene on 
chromosome 21 leads to the development of typical Alzheimer neuropathology secondary 
to the production of too much AE (Selkoe & Hardy, 2016). According to this hypothesis, 
changes in AE metabolism, which may result from genetic mutations, results in a relative 
increase in AE (Raskin, Cummings, Hardy, Schuh, & Dean, 2015). This increase in AE 
results in the formation of plaques, which results in changes in synaptic function and 
local inflammatory responses (Raskin, Cummings, Hardy, Schuh, & Dean, 2015). This 
inflammation results in synaptic loss, neuritic dystrophy and over time oxidative stress 
along with altered neuronal ionic homeostasis and other biochemical changes (Raskin, 
Cummings, Hardy, Schuh, & Dean, 2015). Following these events, tau protein is 
hyperphosphorylated leading to intraneuronal neurofibrillary tangles (Raskin, Cummings, 
Hardy, Schuh, & Dean, 2015). This cascade results in widespread synaptic and neuronal 
dysfunction, as well as, cell death which then leads to extensive AE and tau pathology 
resulting in progressive dementia (Raskin, Cummings, Hardy, Schuh, & Dean, 2015).  
In short, the progression of AD is typically characterized by buildup of amyloid 
plaques followed by the development of neurofibrillary tangles. In the early stages of 
AD, early accumulation of abnormal brain amyloid can be detected in several brain areas 
(e.g., precuneus, posterior cingulate, anterior cingulate and frontal, temporal, parietal 
cortical regions). These amyloid deposits, which can be indicators of early fibrillary 
formation in cognitively intact individuals, are detectable 20 years or more before the 
emergence of any significant neuropsychological deficits (Loewenstein et al., 2017). 
Neurofibrillary tangles, which emerge later in the disease course, have been found to 




(Zec, 1993). Because AD damage often occurs first in the temporal lobe and associated 
structures, deficits in memory and higher-order cognitive functioning are typically 
noticed early on (Salmon & Bondi, 2009; Zec, 1993). As the disease progresses other 
brain areas are affected (e.g. prefrontal and parietal), with motor and sensory cortical 
areas usually remaining intact (Perl, 2010).   
 Neuropsychiatric Symptoms of AD. Neuropsychiatric symptoms (NPS), defined 
as noncognitive behavioral and psychiatric symptoms including disturbances of mood, 
perception, and behavior, are also associated with neurodegenerative diseases (Ismail et 
al., 2016). NPS, which are common in MCI and dementia, have been associated with 
poorer outcomes, increased caregiver burden, increased functional impairment, higher 
rates of institutionalization, poorer quality of life, higher burden of neuropathological 
markers of dementia, and accelerated progression to severe dementia or death (Ismail et 
al., 2016; Lyketsos et al., 2011; Fischer, Ismail, & Schweizer, 2012; Balestreri, 
Grossberg, & Grossberg, 2000; Karttunen et al., 2011; Peters et al., 2015; Zubenko et al., 
1991). Several studies have identified four different types of NPS: hyperactivity (i.e., 
aggression, disinhibition, irritability, aberrant motor behavior and euphoria), psychosis 
(i.e., delusion, hallucination and sleep disorder), affective (i.e., depression and anxiety) 
and apathy (i.e., apathy and appetite disorder) (Zhao et al., 2016; Aalten et al., 2007; 
Cheng et al., 2012). Studies investigating the prevalence rates of NPS have offered mixed 
results, likely due to differences in study settings, population demographics, evaluation 
methods, and severity of cognitive impairment (Zhao et al., 2016; Fuh, 2006; Mega et al., 
1996; Teri et al., 1988). In an effort to produce more precise estimates of NPS prevalence 




reported NPS in those with AD was apathy 49%, followed by depression 42%, 
aggression 40%, anxiety 39%, and sleep disorder 39%. Because NPS commonly occurs 
in neurodegenerative disease such as AD and other dementias, early recognition and 
intervention may aid in improving the prognosis of the patient (Zhao et al., 2016).  
 Neurocognitive Symptoms of AD. Due to pathological changes in the brain, 
which interrupt neural networks, individuals with AD evidence several cognitive deficits. 
In fact, deficits in episodic memory, or the ability to learn and retain new information, is 
considered the clinical hallmark of AD (Weintraub, Wicklund, & Salmon, 2012). 
Research indicates that deficits in episodic memory stem from an individual’s inability to 
properly consolidate and store new information (Broe et al., 2003). What little 
information is consolidated is quickly forgotten and there is rarely an improvement over 
the amount of information an individual can learn across numerous trials (Weintraub, 
Wicklund, & Salmon, 2012). As a result, on measures of immediate and delayed 
memory, individuals with AD evidence impaired performance, with delayed memory 
typically being most impaired (Harciarek & Jodzio, 2005). When given tasks involving 
recognition memory where individuals are given memory cues, individuals with AD 
evidence impaired performance often producing both false positive (i.e., endorsing a 
stimulus as being present when it was not) and false negative errors (i.e., rejecting a 
stimulus when it was present) (Weintraub, Wicklund, & Salmon, 2012). 
 In addition to memory impairment, individuals with AD may also present with 
deficits in other cognitive domains such as language, visuospatial, or executive 
functioning. In those with deficits in language functioning, the individual experiences 




stimulus, verbal comprehension, and semantic verbal fluency (i.e. categories) (McKhann 
et al., 2011;Harciarek & Jodzio, 2005;Weintraub, Wicklund, & Salmon, 2012; 
Rascovsky, Salmon, Hansen, Thal, & Galasko, 2007). 
 The deficits in visuospatial functioning in those with AD include impaired spatial 
cognition (i.e. knowledge about environment), object agnosia (i.e. inability to recognize 
objects), impaired face recognition, simultanagnosia (i.e. inability to perceive more than 
one object at a time), alexia (i.e. inability to read), and constructional apraxia (i.e. 
inability to build, assemble, or draw objects) (Parasuraman, Greenwood, & Alexander, 
2000; Thompson, Stopford, Snowden, & Neary, 2005; McKhann et al., 2011).  
 Deficits in executive functioning include impaired attention (e.g. divided 
attention), reasoning, decision making, judgment (e.g. poor understanding of safety 
risks), and problem solving (e.g. difficulty planning complex or sequential activities) 
(McKhann et al., 2011; Perry & Hodges, 1999).  
 Even with these deficit areas, global deficits in AD are not typically manifested 
until the later stages of the disease when individuals increasingly are affected by agnosia 
(i.e. inability to interpret sensory information), apraxia (i.e. inability to perform 
purposeful motor actions), and aphasia (i.e. loss of ability to understand or express 
speech) (Schoenberg & Scott, 2011). 
AD in African Americans 
 Research investigating knowledge and beliefs about AD between racial groups 
indicates that African Americans have more racial constrained beliefs about the disease 
(Dilworth-Anderson, Gibson, & Burket, 2013; Jett, 2006; Mahoney et al., 2005). For 




difficulty distinguishing memory loss from personality or normal aging (i.e. viewing their 
older relative as just “slipping”) (Dilworth-Anderson, Gibson, & Burket, 2013; Jett, 
2006). When family members observe memory loss, it is often attributed to other health 
conditions (e.g. diabetes, neurosyphilis) or emotional distress (e.g. depression, stress) 
(Potter, Roberto, Brossoie, & Blieszner) rather than a dementing illness. Moreover, 
family members often times report being unsure at which point memory loss becomes 
severe enough to indicate dementia (Potter, Roberto, Brossoie, & Blieszner, 2017; Cahill, 
Pierce, Werner, Darley, & Bobersky, 2015). Additionally, research shows that African 
Americans are significantly more likely than Caucasian Americans to perceive memory 
loss and dementia as a normal part of aging and are thus more likely to accept changes 
rather than viewing them as problematic (Mahoney, Cloutterbuck, Neary, & Zhan, 2005; 
Potter et al., 2017). While some studies attribute these “misconceptions” regarding AD 
symptoms to disparities in education, income, and access to information among African 
Americans, research controlling for these variables still find these racial constrained 
beliefs prevalent among African Americans (Dilworth-Anderson & Gibson, 2002; Lee et 
al., 2012; Connell et al., 2009; Mahoney et al., 2005). 
 Research demonstrates that in the instances where memory loss is viewed as 
problematic, affected individuals and their family members are more likely to seek help 
from other family members, friends, or trusted allies such as the church rather than health 
care providers due to historic discrimination, intergenerational traumatization and current 
experiences of discrimination (Mahoney et al., 2005; Dilworth-Anderson, Gibson, & 
Burket, 2013; Jett, 2006). Mistrust in healthcare providers and the health care system 




slavery and segregation”3 which has been exacerbated by historical ethical violations, 
such as the Tuskegee syphilis experiment (Kennedy, Mathis, & Woods, 2007, p. 57.; 
Boulware, Cooper, Ratner, LaVeist, & Powe, 2003). In fact, study conducted by Green 
and colleagues (1997) found that Fifty-two percent of African Americans were aware of 
the Tuskegee Study and that Twenty-two percent of these individuals reported that 
because of the study they would be less likely to participate in research themselves. 
Exacerbating these factors and reinforcing this narrative are continued concerns about 
interpersonal and technical competence of health care providers, as well as, expectations 
of racism and experimentation during routine health care (Jacobs, Rolle, Ferrans, 
Whitaker, & Warnecke, 2006). Unfortunately these expectations of discrimination, are 
often reinforced by microaggressions (i.e. “brief and commonplace daily verbal, 
behavioral, or environmental indignities, whether intention or unintentional, that 
communicate hostile, derogatory, or negative racial slights”) (Sue, Capodilupo, Torino, 
Bucceri, Holder, Nadal, & Esquilin, 2007) such as African Americans having memory 
concerns dismissed and memory problems attributed to drinking habits (Boulware, et al., 
2003; Mahoney et al., 2005). Furthermore, given the institutionalized racism embedded 
within the United States physicians perceive African Americans more negatively on a 
number of barriers that affect health care (Van Ryn, & Burke, 200), and African 
Americans, particularly those who endorse high perceptions of racism and classism, 
report less satisfaction with health care as well as less treatment adherence (Glover, Sims, 
& Winters, 2017, Cuffee, Hargraves, Rosal, Briesacher, Schoenthaler, Person,... & 
                                                 
3 Interested readers are directed to Kennedy and colleagues (2007) review African 
Americans and Their Distrust of the Health Care System: Healthcare for Diverse 




Allison, 2013; Sims, Diez-Roux, Gebreab, Brenner, Dubbert, Wyatt,... & Taylor, 2016; 
Hausmann, Hannon, Kresevic, Hanusa, Kwoh, & Ibrahim, 2011). Given that majority of 
African Americans relate their experiences of discrimination to race/ethnicity, and 
roughly two thirds of graduating physicians are Caucasian, it is not surprising that 
African Americans report more discrimination and distrust in physicians than any other 
racial or ethnic group (Banks, Kohn-Wood,& Spencer, 2006; Mickelson &Williams, 
1999; Castillo-Page, 2010; Hausmann, et al., 2011; Sims, et al., 2016; Cuffee, et al., 
2013; Jacobs, et al., Glover, et al., 2017). As a result of these factors, conducting medical 
and psychological research within the African American community, including that on 
AD, faces a number of barriers which unfortunately adversely affect the research body 
(Hamel, Penner, Albrecht, Heath, Gwede, & Eggly, 2016). This is particularly 
problematic as the rate of AD in African Americans is higher than that of other group and 
projected to increase as the baby boomers enter late life (Mehta & Yeo, 2017; Colby & 
Ortman, 2017).  
Risk and Protective Factors. Given that the rate of AD in African Americans is 
higher than that of other groups, and a projected increase in this population expected over 
the next few decades, understanding factors that protect or contribute to AD in African 
Americans has become increasingly important (Colby & Ortman, 2017). Research 
examining the higher incidence rates of AD in African Americans points to several risk 
factors, including those in the biological, health, and psychological domains.  
 Biological Risk Factors. One of the most established biological risk factors for 
AD is the prevalence of an Apolipoprotein H4 (APOE H4) genotype (Schoenberg & Scott, 




than in Whites, research has failed to demonstrate a consistent relationship between 
APOE H4 prevalence, AD, and cognitive decline in African Americans (Barnes & 
Bennett, 2014; Logue et al., 2011; Evans et al., 2003; Reitz et al., 2013). A likely reason 
for the inconsistency among research findings to date rests in the fact that, for research 
described above, African Americans are generally underrepresented in AD research, most 
of which involves non-Hispanic Whites (Shin, & Doraiswamy, 2016). Recently, one of 
the largest genome studies involving African Americans was conducted and confirmed 
that the APOE H4 allele, along with the ABCA7 gene, is related to increased risk of 
Alzheimer’s disease among African Americans (Reitz et al., 2013).  
 Health Risk Factors. A number of health conditions more prevalent in the 
African American population such as diabetes, hypertension, and obesity have been 
identified as capable of increasing the risk of developing AD (Barnes & Bennett, 2014; 
Steenland et al., 2016). These health risk conditions occur more often in African 
American populations compared to Whites and are likely the result of environmental, 
biological, and socioeconomic factors (Barnes & Bennett, 2014; Steenland et al., 2016).  
Specifically, African Americans are at least 50% more likely to have diabetes than 
Whites (Signorello et al., 2007; Carter & Pugh, 1996; Centers for Disease Control and 
Prevention, 2003; Mokdad et al., 2003; Harris et al., 1998; Cowie, Harris, Silverman, 
Johnson, & Rust, 1993; & Harris et al., 1990), 51% more likely to be obese (Center for 
Disease Control and Prevention, 2009), and 13% more likely to have hypertension then 
their White peers (Murray et al., 2018; Nwankwo, Yoon, Burt, & Gu, 2013). One 
explanation for this link may be that dementia in African Americans is most often of 




decline (Barnes & Bennett, 2014; Steenland et al., 2016). However, more data is needed 
to investigate the relationship between these conditions and the neuropathology present in 
AD, particularly in the African American population. 
 Psychological Risk Factors. While psychological factors have been shown to 
increase the risk associated with cognitive decline and progression to AD, few studies to 
date have examined these factors in African Americans. For example, both depression 
and chronic stress have been linked to higher rates of AD and since African Americans 
report higher incidence of depression and stress, these psychological factors may play a 
larger role in AD for this population (Turner, Capuano, Wilson & Barnes, 2015; 
Machado et al., 2014; Zannas et al., 2015). Social issues such as racial discrimination 
have also been linked to decreased psychological well-being and higher rates of 
depression and stress in African Americans, as well as, health care satisfaction and 
treatment adherence (Hudson, Neighbors, Geronimus, & Jackson, 2015; Glover, Sims, & 
Winters, 2017; Sims, et al., 2016). As such, more studies are needed to examine 
psychological and sociological factors that negatively impact African Americans and the 
extent to which these factors further contribute the higher incidence of AD seen in this 
population.  
Protective Factors. In addition to the aforementioned risk factors, a number of 
protective factors have been identified within African American communities focused on 
spirituality, religious involvement and family support. Churches have long been viewed 
as trusted organizations within African American communities, and as a result, many 
African American families report relying on their churches for support and as a source of 




Mahoney et al., 2005). Similarly, African American families report a preference to rely 
on trusted and understanding family members and close friends for help rather than 
seeking outside help, with some individuals’ insisting on complete reliance on family due 
to views of familial responsibility (Potter, et al., 2017).  
Studies demonstrate that religious and spiritual involvement along with strong 
family support serves as a protective lifestyle factor for individuals experiencing 
cognitive decline (Agli Bailly, & Ferrand, 2014). Religious attendance and social 
activities (i.e. singing, praying, attending sermons, studying scripture, socializing) have 
been found to benefit cognitive health by promoting active and engaging lifestyles which 
require various cognitive exercises (Hill, 2008; Agli et al., 2014; McNamara, 2002). 
These cognitive exercises strengthen frontal circuits in the brain, train episodic memory, 
improve introspection and attention which may prevent or delay cognitive decline (Hill, 
2008; Agli et al., 2014; McNamara, 2002; Koenig, 2012). Further, religious and social 
involvement provide outlets for psychological stressors, reduce anxiety, reduce 
depression, and provide a greater sense of meaning and life purpose (Hill, 2008). 
Reduced psychological stress protects against elevated blood cortisol levels which may 
otherwise result in hippocampal atrophy and subsequent memory loss (Hill, 2008; 
Conrad, 2008; Csernansky et al., 2006; Sapolsky, 2000).  
For those diagnosed with AD, personal faith, prayer, church connections, and 
family support enabled individuals to keep a positive attitude as they came to terms with 
living with the disease (Agli et al., 2014). Further, individuals who put their lives in the 
hands of a third party, namely God, reportedly feel more confident and secure, felt 




(Stuckey, 2003; Beuscher & Grando, 2009). African Americans providing care to a 
family member diagnosed with AD are also likely to benefit from religious involvement 
and additional family support. Research has shown that African American caregivers 
exhibit higher levels of religiosity compared to their Caucasian counterparts as a response 
to caregiving strains (Dilworth-Anderson, Williams, Gibson, 2002; Wykle & Segall, 
1991) and that this religiosity along with additional family support lead to less caregiver 
burden and stress and more positive appraisals of caregiving (Wilks, Spurlock, Brown, 
Teegen, & Geiger, 2018; Napoles et al., 2010).  
AD Diagnostic Methods 
Traditionally, AD is diagnosed during the later stages of the disease when there is 
evidence of impairment in memory and at least one additional cognitive domain other 
than memory, which interfere with activities of daily living (Dubois et al., 2007). While 
corroborating biomarker evidence may indicate brain pathology early in AD, imaging and 
laboratory assessments are both costly and offer limited diagnostic clarity since known 
biomarkers have also been found across a broad clinical spectrum including cognitively 
normal individuals (McKhann et al., 2011). Thus, in order to gain diagnostic clarity, 
individuals are often referred for a neuropsychological evaluation to assess cognitive 
functioning. Because deficits in memory, and more specifically episodic memory, are the 
hallmark feature of AD, the evaluation of memory performance is essential to determine 
if AD related impairments are present.  
Traditional neuropsychological measures used to assess memory disorders were 
originally developed to identify advanced memory impairments seen in dementia and are 




Loewenstein, 2010). Several studies have found that these traditional measures lack the 
sensitivity needed to detect earlier stages of AD, as cognitive changes occurring during 
this period are more subtle (Rentz et al, 2013; Pettigrew et al., 2015). In fact, research has 
demonstrated that individuals in the preclinical stage of AD, who evidence abnormal 
amyloid and tau deposition, score in the normal range on these traditional measures 
(Rentz et al, 2013; Pettigrew et al., 2015). Because neuropathological changes are present 
up to 20 years or more before observable deficits are present, those individuals at risk of 
further decline may go undetected by traditional measures. Efforts to mitigate this issue 
have examined the sensitivity of composite scores comprised of several traditional 
measures used together; however, it has been shown that his method is also insensitive to 
subtle changes in memory (Loewenstein et al., 2017).  
In addition to their lack of sensitivity, traditional measures also fail to account for 
realistic environmental challenges and individual differences (Loewenstein et al., 2017). 
Specifically, the administration of traditional measures occurs under optimal conditions 
including a quiet environment and minimized distractions. Unfortunately, this pristine 
testing environment does not translate well to the demands in the real-world environment 
in which people are required to use multiple cognitive resources, multitask, and manage a 
wide array of stimuli simultaneously (Loewenstein et al., 2017). As such individuals in 
optimal testing environments are not required to utilize as many cognitive resources and 
therefore typically perform better than they would in the real-world. This is due to the 
fact that these optimal environments allow individuals to employ cognitive reserve and 
compensatory strategies that may mask underlying neuropsychological deficits (Stern, 




In regard to individual differences, traditional measures have largely 
underrepresented minority individuals in their normative samples. Previous normative 
studies have included only a small number of African American participants with diverse 
ages and educational levels and have generally not excluded participants with neurologic 
disease or those who develop dementia after a short follow up (Schneider et al., 2015; 
Lucas et al., 2005; Dotson, Kitner-Triolo, Evans, & Zonderman, 2008; Holtzer et al., 
2008). In addition to insufficient normative data, research has demonstrated racial 
disparities in testing performance. Research has found that African Americans, along 
with other minority groups, typically score lower than Whites on traditional measures of 
verbal and nonverbal abilities despite equivalent education and socioeconomic level 
which further reduces specificity of cognitive impairment (Schneider et al., 2015; 
Mayeux et al., 2011; Snitz et al., 2009; Cerhan et al., 1998). While these studies have 
utilized covariance or matching procedures to equate racial groups based on years of 
education prior to examining test performance, other studies argue that matching based 
on years of education likely does not address performance discrepancies between racial 
groups as the quality of education may not be comparable (Manly et al., 1998; Kaufman 
et al., 1997; Loewenstein et al., 1994; Whitfield & Baker-Thomas, 1999). Research has 
demonstrated that African Americans have reading skills significantly below their self-
reported education levels (Albert & Teresi, 1999; Baker et al., 1996). This discrepancy is 
likely due in part to the history of segregation of schools in the United States (Manly et 
al., 1998). Many older African Americans attended segregated schools which received 
inferior funding, had lower quality teachers, had higher ratios of students to teachers, and 




1990). In addition, African American children were often employed, which reduced their 
school attendance during the year (Margo, 1985). To address this issue, researchers have 
adjusted for quality of education as measured by reading ability rather than years of 
education and have found that the effect of race on test performance was no longer 
significant (Manly et al, 2002).  
Traditional Memory Paradigms. Traditional memory paradigms are based on 
the notion that rapid rate of forgetting and impaired delayed recall is one of the most 
sensitive indicators of AD and can best predict progression to dementia in cognitively 
normal individuals (Loewenstein et al., 2004; Ashford et al., 1989; Locasio et al., 1995; 
Troster et al., 1993; Welsh et al., 1991; Masur et al., 1994). More recently, it has been 
recognized that deficits in initial learning may play a larger role demonstrating that 
attentional resources and learning strategies may impact memory processes (Greenaway 
et al., 2006; Schneider, Boyle, Arvanitakis, Bienias & Bennet, 2007; Loewenstein et al., 
2017; Loewenstein et al., 2003). One of the most common memory paradigms utilized to 
assess both traditional and more recent indicators of AD, is list learning, which includes 
the presentation of stimuli to be remembered over several learning trials. These 
assessments examine different aspects of memory such as storage and consolidation, 
immediate and delayed memory, and recognition of target stimuli (Loewenstein, Curiel, 
Duara, & Buschke, 2017). Neuropsychological assessments based on this traditional 
memory paradigm include the Rey Auditory Verbal Learning Test (Schmidt, 1996), the 
Hopkins Verbal Learning Test-Revised (Brandt & Benedict, 2001), the Buschke 
Selective Reminding Test (Buschke & Fuld, 1974), the California Verbal Learning Test-




Registry for Alzheimer’s Disease List-Learning Test (Morris et al., 1989). Other 
commonly used traditional memory paradigms include the examination of immediate and 
delayed memory for story passages as seen on the Wechsler Memory Scale Fourth 
Edition (WMS-IV) Logical Memory subtest, paired associate learning as seen on the 
WMS-IV Verbal Paired Associates subtest, and retention of simple or complex geometric 
designs as seen on the Brief Visual Memory Test-Revised (BVMT-R) and the Rey 
Complex Figure Test (RCFT) (Wechsler, 2009; Benedict, 1997; Meyers & Myers, 1995; 
Loewenstein, Curiel, Duara, & Buschke, 2017).  
While traditional memory paradigms rely on passive encoding through the 
presentation of stimuli to-be-remembered over several learning trials, newer paradigms 
have employed an active encoding approach. These more active paradigms, termed 
controlled learning paradigms, avoid the limitations of traditional list learning measures 
by providing the examinee with a cue that the to-be-remembered information should be 
organized by, and by doing so, increase the depth of processing and encoding of the 
information presented (Loewenstein et al., 2017; Buschke, Sliwinski, Kuslansky, & 
Lipton, 1995; Buschke, Sliwinski, Kuslansky, & Lipton; 1997; Thomson & Tulving, 
1970). Not only does controlled learning ensure proper processing and encoding but the 
cues used may allow individuals to access information during retrieval (Loewenstein, 
Curiel, Duara, & Buschke, 2018). Studies have shown that individuals with AD are 
unable to properly use these category cues and thus will still demonstrate impaired 
performance (Adam et al., 2007; Grober & Buschke, 1987; Grober Buschke, Crystal, 




In addition, individuals with AD have been found to be susceptible to semantic 
interference, or the ability to deal with competing stimuli within a semantic category, on 
a number of measures (Loewenstein et al., 2003; Loewenstein et al., 2004; Ebert & 
Anderson, 2009; Cushman et al., 1988; Davis et al., 2002). Semantic interference can be 
further differentiated into proactive and retroactive semantic interference. Proactive 
semantic interference (PSI) occurs when old semantic learning interferes with the 
learning of new semantic information (Loewenstein et al., 2017). This is demonstrated by 
list learning measures in which the learning of a first semantic category (Animals) 
repeated over multiple trials interferes with the learning of the same semantic category on 
a second list. For example, if a person is unable to recall a newly presented word to-be-
remembered such as “Dog” because they previously learned and remember the word 
“Cat,” proactive interference has occurred. Retroactive semantic interference (RSI) 
occurs when newly learned semantic information interferes with previously learned 
semantic information (Loewenstein et al., 2017). RSI is demonstrated by list learning 
measures when the recall of the first category of semantic stimuli (Animals) is difficult 
due to interference of the second list of semantic stimuli. For example, if a person is 
unable to recall the word “Tiger” because more recently they were given the word “Lion” 
to remember, retroactive interference has occurred.   
While traditional memory paradigms have examined PSI and RSI, they have 
several limitations that reduce their sensitivity to identifying the earliest stages of AD 
(i.e. preclinical AD and MCI) (Crocco, Curiel, Acevedo, Czaja, & Loewenstein, 2014). 
While some traditional measures may include competing to-be-remembered lists, 




to-be-remembered stimuli which does not allow for the appropriate examination of PSI 
and RSI (Loewenstein, et al., 2017). Uncontrolled learning in these paradigms thus does 
not account for individual attentional resources or learning strategies (Loewenstein et al., 
2018). Furthermore, traditional measures lack multiple trials of the second semantically 
related list which prevents the examination of an individual’s ability to recover from 
proactive semantic interference (Loewenstein et al., 2017). Recovery from PSI is 
valuable in that it represents strong initial learning and memory.  
Taken together PSI, RSI, and recovery from PSI enable us to not only compare an 
individual to a demographically related normative group, but also to their own initial 
learning and retrieval abilities (Loewenstein et al., 2017). Thus, novel measures that 
adequately examine controlled learning, PSI, RSI, and recovery from PSI, may 
demonstrate enhanced sensitivity to the earlier stages of AD which may also prove 
valuable for those racial groups not traditionally represented in normative data.   
Novel Memory Paradigm. A novel paradigm, the Loewenstein-Acevedo Scales 
of Semantic Interference and Learning (LASSI-L), was developed to address the 
aforementioned limitations commonly found in traditional memory paradigms (Curiel et 
al., 2013). The LASSI-L instructs a person to remember a list of 15 common words that 
are organized around three semantic categories (i.e. fruits, musical instruments, articles of 
clothing), with each category consisting of five target words. After reading the list of 15 
words, the examinee is asked to recall the words. This free recall is followed by a cued 
recall in which the person is presented with each category cue and asked to recall the 
words belonging to that category. The person is then presented with the 15 words from 




each category. Then, a second semantically related list (List B) is presented in the same 
manner in which the first list (List A) was administered. Following the presentation of 
List B, the person is asked to free recall List B words, assessing for semantic PSI. Free 
recall of list B is followed by a cued recall. List B words are presented for a second time, 
followed by a second cued recall trial to assess for recovery from PSI. To assess for RSI, 
the person is then asked to freely recall the original List A words. This is followed by a 
cued recall of List A. After a 20-minute delay the person is asked to freely recall words 
from both Lists A and B.  
The LASSI-L demonstrates several strengths over traditional memory paradigms 
(Loewenstein et al., 2017). First, the LASSI-L explicitly identifies the semantic 
categories which learning should be organized before target words are presented. This 
explicit identification decreases the impact that attentional resources and learning 
strategies may have on memory. Second, the LASSI-L provides a second list of words in 
which each word is semantically related to a target on the first list. Third, multiple 
exposures to both List A and List B increase encoding by increasing the depth of initial 
processing of to-be-remembered information. Lastly, the LASSI-L provides the 
evaluation of PSI and RSI as well as a unique measure of recovery from PSI.   
LASSI-L Clinical Findings. Validation studies of the LASSI-L have 
demonstrated high test-retest reliability as well as high concurrent and discriminant 
validity (Loewenstein & Acevedo, 2005; Curiel et al., 2013). Several studies have 
demonstrated the LASSI-L’s ability to differentiate between cognitively normal (CN) 
individuals and those ranging in severity of impairment (Curiel et al., 2013; Loewenstein 




demonstrated high levels of sensitivity and specificity with an overall correct 
classification rate of 90%, which is significantly higher than classification rates obtained 
by traditional neuropsychological assessment measures (Curiel et al., 2013; Crocco, 
Curiel, Acevedo, Czaja, & Loewenstein, 2014). Similar results were obtained for a 
validation study of the LASSI-L among Spaniards (Matias-Guiu et al., 2016). In regard to 
severity of impairment, Crocco and colleagues (2014) found that amnestic MCI (aMCI) 
patients evidenced higher PSI and RSI effects than CN individuals. These PSI and RSI 
effects are due to the LASSI-L’s high degree of shared semantic cueing, which elicits 
significant numbers of semantic intrusions, particularly for impaired individuals.  
Loewenstein and colleagues (2016) examined the LASSI-L in individuals ranging in 
degree of cognitive impairment and found that deficits on the LASSI-L were observed in 
89% of those with MCI, 47% of those with preclinical MCI, 33% with subjective 
memory complaints, and 13% of those classified as normal. 
 The LASSI-L has also been shown to correlate with biomarker evidence and brain 
structural changes associated with AD. In regard to biomarker evidence, the LASSI-L has 
been shown to correlate to amyloid depositions (Loewenstein et al., 2017). Specifically, 
deficits on initial learning of List A on the LASSI-L was found to significantly correlate 
with amyloid depositions in the anterior cingulate (-.49) and frontal lobes (-.44) 
(Loewenstein et al., 2017). When looking at different diagnostic groups (i.e. subjective 
memory complaints, preclinical MCI, and MCI), all evidenced deficits in recovery from 
PSI which was associated with increased amyloid deposition throughout the entire brain 




-.48) (Loewenstein et al., 2017). Taken together, these results indicate that the LASSI-L 
is sensitive to subtle cognitive impairments and increasing amyloid load.  
Studies investigating the LASSI-L and its association to volumetric loss in AD 
prone brain areas has found that preclinical MCI individuals evidenced greater LASSI-L 
deficits particularly with regards to failure to recover from PSI and delayed recall. These 
deficits were associated with increased dilation of the inferior lateral ventricle and 
decreased MRI volumes in the hippocampus, precuneus, superior parietal region, and 
other AD prone areas (Crocco et al., 2018). Similar results have been observed in 
individuals with aMCI. Specifically, aMCI patients who demonstrated failure to recover 
from PSI evidenced reduced volumes in the hippocampus (rs=0.49); precuneus (rs = 
0.50); rostral middle frontal lobules (rs = 0.54); inferior temporal lobules (rs = 0.49); 
superior parietal lobules (rs = 0.47); temporal pole (rs = 0.44); and increased dilatation of 
the inferior lateral ventricle (rs = −0.49) (Loewenstein et al., 2017).  Taken together these 
results demonstrate that performance on the LASSI-L and more specifically observed 
frPSI is uniquely and strongly related to volumetric loss in AD prone brain areas.  
Clinical Relevance. With the growing number of diverse older adults and rates of 
AD expected to increase dramatically over the next few decades, a variety of initiatives 
have pushed for an earlier detection of AD in order to provide better treatment (Albert et 
al., 2011; Sperling et al., 2011; Dubois et al., 2016). Theoretically, early detection would 
allow for earlier treatment or interventions with disease modifying therapies before the 
onset of dementia (Dubois et al, 2016). While no such intervention or therapy currently 
exists, early interventions may benefit patients by stopping or significantly slowing the 




(Dubois et al., 2016). An intervention of this ability would dramatically reduce health 
care costs. Projections estimate that an intervention that delayed the onset of AD 
dementia by 5 years would result in a 57% reduction in the number of patients affected 
which would reduce the costs of Medicare from $627 to $344 billion dollars (Sperling et 
al., 2011). This delay would also result in prolonged functional independence and greater 
quality of life for patients and their families. Patients and their families would then be 
able to better plan and prepare for the future by having the opportunity to make living, 
care, financial and legal arrangements while they still have preserved insight (Antoine & 
Pasquier, 2013; Holt, 2011; Mattsson, Brax, & Zetterberg, 2010; Dubois et al., 2016).  
Early detection would also allow those in healthcare to better serve patients. 
Physicians would have the opportunity to offer therapies that address symptoms such as 
anxiety or impaired sleep while also monitoring prescribed medications that could 
inadvertently exacerbate dementia (Dubois et al., 2016). With the clear benefits of early 
detection and promise of novel disease modifying pharmacological interventions on the 
horizon, it is increasingly important to develop diagnostic tools capable of identifying 





Chapter 2: Purpose and Specific Aims 
 
 
The purpose of this dissertation study is to extend the body of research on 
effective early detection of AD in African Americans. While the LASSI-L has 
demonstrated effectiveness above and beyond traditional measures at differentiating 
between normal individuals and those ranging in severity of impairment, these studies 
have largely consisted of White and Hispanic individuals. Therefore, this study will 
examine the performance of African Americans, both cognitively normal and those with 
amnestic-mild cognitive impairment, on the LASSI-L. Further, this study will assess if 
the LASSI-L serves as a better predictor of diagnostic group classification and MRI 
volumetric reductions in AD prone areas in African Americans compared to traditional 
neuropsychological measures.  
This dissertation was designed to fulfill three specific aims, which, along with the 
related research questions, are detailed below.  
Specific Aim 1: Explore Whether There are Differences in Performance on the LASSI-
L Between aMCI and Cognitively Normal African American Older Adults.  
Research Question 1a. When cognitive status is grouped by amnestic-MCI and 
cognitively normal are there statistically significant differences in African American 
older adults cognitive status when examined in terms of LASSI-L measures reflecting 
initial learning and storage of information?  
Research Question 1b.  When cognitive status is grouped by amnestic-MCI and 
cognitively normal are there statistically significant differences in African American 




proactive semantic interference (PSI) and failure to recover from proactive semantic 
interference (frPSI)? 
Research Question 1c.  When cognitive status is grouped by amnestic-MCI and 
cognitively normal are there statistically significant differences in African American 
older adults cognitive status when examined in terms of LASSI-L measures reflecting 
retroactive semantic interference (RSI)? 
Research Question 1d. When cognitive status is grouped by amnestic-MCI and 
cognitively normal are there statistically significant differences in African American 
older adults cognitive status when examined in terms of LASSI-L measures reflecting 
delayed recall? 
Research Question 1e. After controlling for covariates, are there differences on 
LASSI-L measures by diagnostic group in African American older adults. 
Specific Aim 2: To Determine if Performance on the LASSI-L Serves as a Better 
Predator of Diagnostic Group Classification Compared to Other Neuropsychological 
Tests in African American Older Adults. 
Research Question 2a. What is the relationship between scores obtained on the 
LASSI-L and diagnostic group classification in African American Older Adults?  
Research Question 2b. What is the relationship between scores on traditional 
neuropsychological measures and diagnostic group classification in African American 
Older Adults?  
Specific Aim 3: To Explore How Neuropsychological Measures are Related to 




Research Question 3a. Are LASSI-L measures of PSI and frPSI related to MRI 
Volumetric Reductions in left hemisphere AD prone regions? 
Research Question 3b. Are Traditional Neuropsychological Measures related to 








Chapter 3: Methods 
 
 
Participants and Procedure 
 This dissertation study examined 44 (28 male, 16 female) independent community 
dwelling African Americans aged 60-years-old or older (mean age=64.5 years, SD= 
4.45), with the vast majority having a high school education (mean=12.4; SD=1.66). 
Participant data was selected from an NIH-funded study at the University of Miami 
School of Medicine, which was designed to measure the longitudinal trajectories of 
decline in PreMCI participants. Participants in this NIH-funded study were recruited from 
the University of Miami’s Center on Aging/CREATE Center as well as the Memory 
Disorder Clinic. Interested individuals were prescreened for eligibility through an 
extensive clinical interview, which included the Neuropsychiatric Inventory (NPI), Mini-
Mental State Examination (MMSE) (Folstein et al., 1975), and Clinical Dementia Rating 
Scale (CDR) (Morris, 1993). Participants and their informants signed Informed Consent 
forms. Eligible participants, who were 60 years of age or older and did not meet DSM-5 
criteria for Major Neurocognitive Disorder, active Major Depressive Disorder, active 
Substance Use disorder in the last 6 months, or any other neuropsychiatric diagnosis, 
were subsequently administered a standard neuropsychological battery. Measures 
selected for this study, which are described below, took approximately 45 minutes to 
complete and included the Hopkins Verbal Learning Test -Revised (Benedict et al., 
1998), National Alzheimer’s Coordinating Center (NACC) delayed paragraph recall 
(Beekly et al., 2007), Category Fluency (Lucas et al., 1998), the Block Design subtest 
from the Wechsler Adult Intelligence Scale, Fourth-Edition (Wechsler, 2008), and Trail 




Semantic Interference and Learning (LASSI-L) was also administered but was not used 
for diagnostic determination. Participants received a stipend of fifty dollars for 
completing these assessments.  
Diagnostic determination was based on the independent clinical interview and 
performance on the neuropsychological tests. Participants were diagnosed as cognitively 
normal (CN) if: a) there was no subjective memory complaints by the participant and/or 
collateral informant; b) no evidence by clinical evaluation or history of memory or other 
cognitive decline ; c) Global Clinical Dementia Rating Scale of 0; d) the 
neuropsychological battery was deemed normal and generally no measures in the 
neuropsychological battery fell 1 standard deviation or more below normal limit relative 
to age and education normed data. Participants were diagnosed with Amnestic-MCI 
(aMCI) if: a) there was subjective memory complaint by the participant and/or collateral 
informant; b) Global Clinical Dementia Rating Scale of 0.5; c) no impairment in social 
and/or occupational function; d) neuropsychological testing confirmation of memory 
impairment as evidenced by performance  at or  below 1.5 standard deviations expected 
for age and education adjusted normative data on the HVLT-R delayed recall or NACC 
delayed paragraph recall.  
After completing neuropsychological testing, interested and eligible participants 
also received MRI scans (n=29). Participants signed separate informed consent forms for 
this portion of the study. MRI scans were performed with the 3T Siemens Trio scanner at 
the Applebaum Diagnostic Imaging Center, University of Miami Health System, with 
assistance of the staff MRI technologists. Total imaging time for each participant was 




undergoing MRI scans. Psychometrists scoring the cognitive/neuropsychological and 
functional evaluations as well as those individuals providing MRI analyses were blind to 
participant diagnosis.  
For the purpose of this dissertation all participants self-identifying as African 
American on a demographic form were selected. Participants were excluded from the 
present study’s dataset if they reported a race or ethnicity other than African American 
(e.g. Haitian, Cuban, Hispanic)(n=396) and if they did not complete the full 
neuropsychological battery (n=5). 
Measures 
 The following measures will be described below: Neuropsychiatric Inventory 
(NPI), Mini-Mental State Examination (MMSE), Clinical Dementia Rating Scale (CDR), 
Hopkins Verbal Learning Test-Revised (HVLT-R), National Alzheimer’s Coordinating 
Center (NACC) Delayed Paragraph Recall, Category Naming Fluency, Wechsler Adult 
Intelligence Scale, Fourth-Edition (WAIS-IV) - Block Design subtest, Trail Making Test, 
and the Loewenstein-Acevedo Scale for Semantic Interference and Learning (LASSI-L). 
 Neuropsychiatric Inventory (NPI). The Neuropsychiatry Inventory was 
developed to assess a wide range of behavior problems common in individuals with 
dementia. Ten distinct behavior domains are assessed: delusions, hallucinations, 
dysphoria, anxiety, euphoria, agitation/aggression, apathy, irritability/lability, 
disinhibition, and aberrant motor behavior. Scripted questions are asked to an informant, 
ideally a daily caregiver, about the individual’s behavior in the past month. Each section 
has screening questions; if the behavior has occurred, more detailed questioning assesses 




the tests also assesses for sleep and appetite/eating disorders (Cummings, 1997). This 
revision also introduced a 6-point caregiver distress scale which ranges from 0 (no 
distress) to 5 (very severe distress), which were added to each domain. The suggested 
administration time for the original scale was anywhere from 7 to 10 minutes, although 
that number is dependent on the informant and how much information they provide.  
The NPI has produced high interrater reliability and internal consistency 
(Cummings, Mega, Gray, et al., 1994). Test-retest reliability by a second interviewer 
within three weeks was generally adequate, with the lowest correlations for 
irritability/lability. Neuropsychological findings suggest that all behavior problems 
assessed by the NPI were greater in AD patients compared to age-matched control 
subjects, of which, the most common was apathy, which was exhibited by 72% of 
patients. The NPI has been used successfully to differentiate the behavioral symptoms of 
AD and PD (Aarsland et al., 2001), it has also been used to assess psychiatric symptoms 
in many subcortical, neurodegenerative disorders (Litvan, Cummings, & Mega, 1998). 
Mini-Mental State Examination (MMSE). The MMSE is a cognitive screener 
widely used for dementia (Milne et al., 2008). The test assesses a restricted set of 
cognitive functions simply and quickly, as a result the standardized administration only 
takes about 5 to 10 minutes. A perfect score on the MMSE is 30 points. Points are 
obtained from several domains including: working memory (serial 7s and spelling 
“world” backwards); language and praxis (naming, following commands, and 
construction); orientation; memory (delayed recall of three items); and attention span 




 MMSE scores decrease with age and increase with education (Tombaugh & 
McIntyre, 1992). Less educated individuals tend to make errors on the first serial 
subtraction, spelling backwards, repeating phrases, writing, naming the season, and 
copying (Jones & Gallo, 2002). Cultural and educational limitations need to be 
considered as they may lower scores below the cut-off of no cognitive impairment of 24. 
African Americans and Hispanics are more likely than European Americans to have been 
erroneously identified as demented (Espino et al., 2001). Test-retest reliability over 24 
hours for nondemented psychiatric inpatients was high (r = .89, same examiner; r = .83, 
different examiner) (Folstein, Folstein, & McHugh, 1975). Four-week test-retest 
reliability for dementia patients was nearly perfect (r = .99) (McCaffrey, Duff, and 
Westervelt, 2000). The MMSE is most effective in distinguishing patients with moderate 
or severe deficits from control subjects (Tombaugh & McIntyre, 1992). It is not as 
effective at differentiating between mildly demented patients from normal subjects 
(Knight, 1992).   
Clinical Dementia Rating Scale (CDR). The CDR compares AD patients with 
healthy controls in six categories of cognitive functioning (i.e. memory, orientation, 
judgement and problem solving, community affairs, home and hobbies, and personal 
care) (Berg et al., 1988). The instrument is administered via a semi-structured interview 
to both the participant and an informant (e.g., relative, caregiver). The score is calculated 
algorithmically and given on a 5-point scale of impairment (0 = no impairment, 0.5 = 
questionable, 1 = mild, 2 = moderate, 3 = severe) (Morris, 1993).  There are several 
factors that contribute to the utility of the CDR: 1) the six categories used for rating 




Mckeel, Fulling, Torack, & Berg, 1988); 2) it has high inter-rater reliability for both 
physicians (Burke et al., 1988) and nonphysicians (McCulla et al., 1989); and 3) an 
expanded and more quantitative version of the scale can be obtained by summing the 
ratings in each of the six categories to provide an overall sum score (Berg et al., 1988). 
Hopkins Verbal Learning Test -Revised (HVLT-R). The HVLT-R is a list 
learning task comprised of 12 words, four in each of three semantic categories for three 
learning trials. Following a 20 to 25-minute delay patients are asked to recall as many 
words as they are capable of. Immediately after the delayed recall a 24-word yes/no 
recognition trial is administered containing all 12 target words plus six semantically 
related words and six unrelated ones. Scores include one for each learning trial, a total 
acquisition score, a learning measure, delayed free recall, percent retention, and delayed 
recognition. Recognition scores are calculated for true positives, false positives, a 
discrimination index, and a measure of the recognition trial response bias.  
  A test-retest interval of one year for middle-aged adults produced a moderate total 
recall reliability correlation (r = .49) while delayed recall reliability was significant but 
lower (r = .36) (Woods et al, 2005). Several variables (i.e. percent retained, learning, 
intrusions, and repetitions) indicated lower reliability. Validity studies demonstrated the 
comparability of HVLT-R recall and recognition measures to memory measures form 
other tests, particularly verbal memory tests (Lacritz et al., 2001; Shapiro et al., 1999). 
Neuropsychologically, patients with AD exhibit a learning deficit on the HVLT-R 
(Hogervorst et al., 2002). Further, they are more likely to say “yes” to semantically 




National Alzheimer’s Coordinating Center (NACC) Delayed Paragraph 
Recall. NACC delayed paragraph recall requires the subject to recall a story read aloud 
by the examiner, both immediately and after a 20-minute delay. Scoring allows several 
acceptable responses for each item recalled. Participants can gain points by paraphrasing, 
but a verbatim score can also be obtained from allocating a point for each item recalled 
exactly as delivered in the story. The verbatim score was intended to serve as potentially 
more sensitive than the paraphrase score in detecting very early memory decline (Craft et 
al., 2000). The reliability coefficient of the immediate condition for the normative sample 
by age group ranged from adequate to high (.77-.88) while delayed recall was high (.80-
.90) (WMS-IV Technical Manual, 2008). The test-retest reliability of the paragraph recall 
was adequate for both the immediate and delayed conditions (.70-.79) (WMS-IV 
Technical Manual, 2008). Delayed paragraph recall is also sensitive to AD. Participants 
with AD scored significantly lower than matched controls on the delayed condition, with 
this difference producing a large effect size (2.20). 
Category Naming Fluency. In this task, individuals are simply asked to name as 
many animals, fruits, and vegetables that they can think of, without being given any other 
cues or restrictions. Individuals with disorders such as those affecting the temporal lobe 
have demonstrated category deficits. Temporally-based disorders such as Alzheimer’s 
Disease, demonstrate this deficit, which can be attributed to a breakdown in sematic 
knowledge about different categories. Normative data for the Category Naming test is 
further stratified by age, sex, and education. Contemporary practitioners favor the use of 




Additional normative data has also been created for Spanish speakers living in the United 
States (Acevedo et al., 2000). 
Test-retest correlations tend to be high, usually higher than .70 for semantic 
fluency with short (e.g., one week) as well as long (e.g., five years) intervals (Basso et al., 
1999; Ross, 2003; Levine et al., 2004). Practice effects can be observed after short retest 
intervals. Wilson et al. (2000) showed that fluency for the same category shows a small 
but consistent increase across 20 administrations over a span of four weeks. This increase 
was observed in normal participants as well as those who had sustained head injuries. 
Validity studies looking at correlations between different semantic category tasks (e.g., 
animals, vegetables) are moderately high (.66-.71; Riva et al., 1999); however, the values 
are not satisfactorily high to establish equivalency among forms.  
Block Design Subtest from the Wechsler Adult Intelligence Scale, Fourth-
Edition. In Block Design, the individual is presented with red and white blocks: two, 
four, or nine, depending on the item they are working on. Each block has two white sides, 
two red sides, and two half-red half-white sides with the colors divided along the 
diagonal. The participant is required to use the blocks to produce replicas of a model 
design presented by the examiner within a given amount of time. Block Design items are 
presented in order of increasing difficulty. On the sample item and the first four items, 
the model design is presented both as a construction made by the examiner and a design 
pictured in the test stimulus book. For the next ten items, the model design is presented 
only as a picture in the test booklet. The sample item and items 1 and 2 use two blocks; 
items 3 to 10 use four blocks; and items 11 through 14 use nine blocks. The WAIS-IV 




not obtain a perfect score on either item 5 or 6, the preceding items are administered in 
reverse order until the examined obtains a perfect score on two consecutive items.   
The technical manual reports split-half reliability coefficients for 13 age groups: 
these coefficients are all at or above .80 (PyschoCorp, 2008b). Test retest reliability of 
the WAIS-IV Block Design for 298 subjects retested over intervals of eight to 82 days 
was .80 overall. Test-retest data show a notable improvement from first testing to second 
testing, suggesting a significant practice effect. Neuropsychologically, Block Design is 
generally recognized as the best Weschler scale measure of visuospatial organization. 
Scores tend to be lower in the presence of any kind of brain impairment, indicating that 
test performance is affected by multiple factors. Specifically, for patients with AD, Block 
Design scores correctly classified 91% of AD patients (Weintraub, Wicklund, & Salmon, 
2012).  Block Design has also proven to be a useful predictor of the disease as a relatively 
low Block Design score in the early stages, when the diagnosis is still in question, may 
herald the onset of the disease (Arnaiz et al., 2001). The test is also one of the most useful 
neuropsychological tests for predicting which patients will deteriorate the most rapidly 
(Small et al., 1997). 
Trail Making Test (Parts A and B). The Trail Making Test measures cognitive 
flexibility, sequencing ability, and visual-motor speed. The Trail Making Test (parts A 
and B) are a subtest from the Army Individual Test (1944) used as measures of attention, 
scanning, visual-motor tracking, divided attention, and set-shifting abilities. Trails A is a 
measure of visual scanning and motor speed.  In Trails A, the participant is given a page 
with a set of numbered circles scatters about the page and is asked to draw a line between 




requires reasoning ability other higher-order processes (Golden, Espe-Pfeifer, & 
Wachsler-Feider, 2000; Kortte, Horner, & Windham, 2002). In Trails B, the participant is 
given a sheet with randomly distributed circled numbers and circled letters and asked to 
draw a line connecting A-1, B-2, C-3, and so forth in a sequencing pattern. Scores are 
based on total time to complete task, and the number of errors made. Cut-off scores were 
used in the original interpretation of the test (Reitan & Wolfson, 1985), but contemporary 
practitioners favor the sensitive of the use of t-scores based normative groups established 
by Heaton in 2004 (Strauss, Sherman, & Spreen, 2006). Test-retest reliability has been 
shown to vary depending on age and population studied. A study looking at 384 normal 
adults aged between 15 and 83 years who were retested about 11 months after the initial 
test session showed adequate reliability for Part A (.79) and high for Part B (.89). Similar 
findings were reported by Levine et al. (2004) for mostly Caucasian, well-educated male 
subjects (.70 for A and B). Mitrushina and Satz (1991) examined test-retest reliability in 
older adults after a 1-year period and found coefficients that were low for part A (.53-.64) 
and higher for part B (.67-.72). Interrater reliability has been reported as .94 for Part A 
and .90 for Part B (Fals-Stewart, 1991). As for sensitivity, the Trail Making Test is 
sensitive to dementing disorders such as AD (Chen et al., 2000); however, the task does 
not distinguish adequately among dementing disorders (Barr et al., 1992).   
Loewenstein-Acevedo Scale for Semantic Interference and Learning (LASSI-
L). The LASSI-L instructs a person to remember a list of 15 common words that are 
fruits, musical instruments or articles of clothing (five words per category). The person is 
asked to read the words for the target list out loud as each is presented individually at 4-




word is read by the examiner and the person is asked to repeat the word. After the person 
has read all 15 words, they are asked to recall the words. After free recall has ended, they 
are presented with each category cue (e.g., clothing) and asked to recall the words that 
belonged to that category. Participants are then presented with target stimuli for a second 
learning trail with subsequent cued recall to strengthen the acquisition and recall of the 
List A targets. The exposure to the semantically related list (i.e., List B) is then conducted 
in the same manner as exposure to List A. List B consists of 15 words different from List 
A, 5 of which belong to each of the three categories used in List A (i.e., fruits, musical 
instruments, articles of clothing). 
Following the presentation of the List B words, the person is asked to free recall 
the List B words, assessing proactive interference effects. Then, each category cue is 
given, and they are asked to recall each of the List B words that belonged to each of the 
categories. List B words are presented again, followed by a second category-cued recall 
trial. Finally, to assess retroactive interference they are asked to free recall the original 
list A words. Free-recall and cued recall scores for List A and List B targets are then 
obtained after a 30-minute delay. Primary measures for this project are the second cued 
recall score, and first cued recall score for list B. Test-retest reliabilities were high and 
the accuracy of classification of aMCI patients versus elderly subjects exceeded 90% (see 





Chapter 4: Results 
  
 
The main objective of this study was to examine the performance of African 
Americans, both cognitively normal and those with amnestic-mild cognitive impairment, 
on a novel cognitive stress test, the Loewenstein-Acevedo Scale of Semantic Interference 
and Learning (LASSI-L) Each of the study’s three specific aims and their associated 
results are presented below:   
Specific Aim 1: Explore Whether There are Differences in Performance on the LASSI-
L Between aMCI and Cognitively Normal African American Older Adults.  
Assumption analyses included boxplots of all dependent variables to assess for 
outliers, and interpretation of the Shapiro-Wilk’s test to determine normality (as n < 50). 
There were no outliers in the data, as assessed by inspection of boxplots. Data was 
normally distributed, as assessed by Shapiro-Wilk's test (p > .05).  For each dependent 
variable there was homogeneity of variances, as assessed by Levene’s test for equality of 
variances with the exception of LASSI-L List A Free Recall 1 Intrusions, p= .001; 
LASSI-L List A Cued Recall 1 Intrusions, p= .000; LASSI-L List A Cued Recall 2 
Intrusions, p=.000; LASSI-L List B Cued Recall 1 intrusions, p= .021. For the instances 
in which Levene’s test for equality of variance was violated, a series of non-parametric 
Mann Whitney U tests of ranks was performed. Because results were the same for 
parametric and nonparametric analysis they were still interpreted.  
Research Question 1a. When cognitive status is grouped by amnestic-MCI and 
cognitively normal are there statistically significant differences in African American 
older adults cognitive status when examined in terms of LASSI-L measures regarding 




A one-way analysis of variance (ANOVA) was conducted to evaluate the research 
question of whether there were statistically significant differences in African American 
older adult cognitive status when examined in terms of LASSI-L measures regarding 
initial learning and storage of information. A criterion for significance of p < .05 was 
used. When examining initial learning and storage of information, cognitively normal 
(CN) individuals were found to recall significantly more words than those with aMCI 
(Table 4-1). For instance, on the LASSI-L List A Free Recall 1, CN individuals recalled 
significantly more words (M= 8.37) compared to aMCI individuals (M= 6.25), F(1,42)= 
8.36, p= .006. Similar results were seen on the LASSI-L List A Cued Recall 1 where CN 
individuals recalled significantly more words (M=9.79) compared to aMCI individuals 
(M=7.70), F(1,42)= 8.34, p= . 006) and on the LASSI-L List A Cued Recall 2, where CN 
individuals recalled significantly more words (M=12.70) compared to aMCI individuals 
(M=10.25), F(1,42)= 25.94, p= .000. Furthermore, on the LASSI-L List A Cued Recall 1, 
CN individuals made significantly fewer intrusions (M=0.25) compared to aMCI 
individuals (M=1.05) F(1,42)= 8.27, p=.006. Similar results were seen on the LASSI-L 
List A Cued Recall 2, where CN individuals made significantly fewer intrusions 
(M=0.12) compared to aMCI individuals (M=.95) F(1,42)=11.309, p= .002. The number 
of intrusions made during the initial free recall on the LASSI-L List A Free Recall 1 did 
not significantly differ between CN (M=.17) and aMCI (M=.45) individuals 







Table 4-1. ANOVA Summary Table for LASSI-L Initial Learning and Storage 
  SS df MS F p 
LASSI-L List A Free Recall 1      
 Between Groups 49.261 1 49.261 8.364 .006* 
 Within Groups 247.375 42 5.890   
 Total 296.636 43    
      
LASSI-L List A Cued Recall 1      
 Between Groups 47.728 1 47.728 8.347 .006* 
 Within Groups 240.158 42 5.718   
 Total 287.886 43    
       
LASSI-L List A Cued Recall 2      
 Between Groups 65.928 1 65.928 25.949 .000* 
 Within Groups 106.708 42 2.541   
 Total 172.636 43    
       
LASSI-L List A Free Recall 1 
Intrusions 
     
 Between Groups .876 1 .876 2.994 .091 
 Within Groups 12.283 42 .292   
 Total 13.159 43    
       
LASSI-L List A Cued Recall 1 
Intrusions 
     
 Between Groups 6.982 1 6.982 8.272 .006* 
 Within Groups 35.450 42 .844   
 Total 42.432 43    
       
LASSI-L List A Cued Recall 2 
Intrusions 
     
 Between Groups 7.425 1 7.425 11.309 .002* 
 Within Groups 27.575 42 .657   
 Total 35.000 43    






Research Question 1b.  When cognitive status is grouped by amnestic-MCI and 
cognitively normal are there statistically significant differences in African American 
older adults cognitive status when examined in terms of LASSI-L measures reflecting 
proactive semantic interference (PSI) and failure to recover from proactive semantic 
interference (frPSI)? 
A one-way analysis of variance was conducted to evaluate the research question 
of whether there were statistically significant differences in African American older adult 
cognitive status when examined in terms of LASSI-L measures reflecting proactive 
semantic interference (PSI) and failure to recover from proactive semantic interference 
(frPSI). A criterion for significance of p < .05 was used. On LASSI-L measures reflecting 
PSI, (Table 4-2), results demonstrated higher scores for those who were CN compared to 
those with aMCI. For instance, on the LASSI-L List B Free Recall those who were CN 
freely recalled more words (M= 6.45) than those with aMCI (M= 4.85). This difference 
was statistically significant, F(1,42) = 5.85, p= .020. On LASSI-L List B Cued Recall 1 
those who were CN recalled more words when cued (M= 7.16) than those with aMCI 
(M= 5.00). This difference was statistically significant, F(1,42)= 8.424, p= 
.006.Intrusions on LASSI-L List B Cued Recall 1 were also statistically significant 
F(1,42) = 25.78, p= .000 with CN individuals making fewer intrusions (M= 3.24) than 
those with aMCI (M= 7.07) F(1,42) = 25.78, p= .000. The number of intrusions made 
during free recall on the LASSI-L List B Free Recall did not significantly differ between 
CN (M=1.67) and aMCI (M=2.20) individuals F(1,42)=.85, p= .36.   
Similar results were observed for the LASSI-L measure reflecting frPSI, LASSI-L 




10.79) than those with aMCI (M= 8.25). This difference was statistically significant 
F(1,42)= 13.472, p= .001. The number of intrusions made during List B Cued Recall 2 
did not significantly differ between CN (M=2.5) and aMCI (M=3.65) individuals 








Table 4-2. ANOVA Summary Table for LASSI-L PSI and frPSI measures 
  SS df MS F p 
LASSI-L List B Free Recall 1      
 Between Groups 28.219 1 28.219 5.853 .020* 
 Within Groups 202.508 42 4.822   
 Total 230.727 43    
      
LASSI-L List B Cued Recall 
1 
     
 Between Groups 51.212 1 51.212 8.424 .006* 
 Within Groups 255.333 42 6.079   
 Total 306.545 43    
       
LASSI-L List B Cued Recall 
2 
     
 Between Groups 70.473 1 70.473 13.472 .001* 
 Within Groups 219.708 42 5.231   
 Total 290.182 43    
       
LASSI-L List B Free Recall 1 
Intrusions 
     
 Between Groups 3.103 1 3.103 .854 .361 
 Within Groups 152.533 42 3.632   
 Total 155.636 43    
       
LASSI-L List B Cued Recall 
1 Intrusions 
     
 Between Groups 119.401 1 119.401 25.782 .000* 
 Within Groups 194.508 42 4.631   
 Total 313.909 43    
       
LASSI-L List B Cued Recall 
2 Intrusions 
     
 Between Groups 14.427 1 23.201 3.965 .063 
 Within Groups 166.550 42 7.303   
 Total 180.977 43    






Research Question 1c.  When cognitive status is grouped by amnestic-MCI and 
cognitively normal are there statistically significant differences in African American 
older adults cognitive status when examined in terms of LASSI-L measures reflecting 
retroactive semantic interference (RSI)? 
A one-way analysis of variance was conducted to evaluate the research question 
of whether there were statistically significant differences in African American older adult 
cognitive status when examined in terms of LASSI-L measures reflecting retroactive 
semantic interference (RSI). A criterion for significance of p < .05 was used. On LASSI-
L measures reflecting retroactive interference (Table 4-3.), results demonstrated higher 
scores for CN individuals compared to those with aMCI. For instance, on the LASSI-L 
List A Free Recall 2 short delay those who were CN freely recalled more words (M=6.45) 
than those with aMCI (M=4.38), F(1,42) = 4.65, p= .037. The number of intrusions made 
during LASSI-L List A Free Recall 2 short delay did not significantly differ between CN 
(M=2.29) and aMCI (M=3.75) individuals F(1,42)=3.18, p= .08. The number of words 
recalled during LASSI-L List A Cued Recall 1 after delay did not significantly differ 
between CN (M=7.46) and aMCI (M=6.50) individuals F(1,42)=1.36, p= .25. Similarly, 
the number of intrusions made during LASSI-L List A Cued Recall 1 after delay did not 








Table 4-3. ANOVA Summary Table for LASSI-L RSI measures 
  SS df MS F p 
LASSI-L List A Free Recall 2 
Short Delay 
     
 Between Groups 28.219 1 28.219 4.652 .037* 
 Within Groups 252.758 42 6.066   
 Total 282.977 43    
      
LASSI-L List A Cued Recall 
1 After Delay 
     
 Between Groups 10.019 1 10.09 1.362 .250 
 Within Groups 308.958 42 7.356   
 Total 318.977 43    
       
LASSI-L List A Free Recall 2 
Short Delay Intrusions 
     
 Between Groups 23.201 1 23.201 3.177 .082 
 Within Groups 306.708 42 7.303   
 Total 329.909 43    
       
LASSI-L List A Cued Recall 
1 After Delay Intrusions 
     
 Between Groups 12.607 1 12.607 1.305 .260 
 Within Groups 405.825 42 9.662   
 Total 418.432 43    






Research Question 1d. When cognitive status is grouped by amnestic-MCI and 
cognitively normal are there statistically significant differences in African American 
older adults cognitive status when examined in terms of LASSI-L measures regarding 
delayed recall? 
A one-way analysis of variance was conducted to evaluate the research question 
of whether there were statistically significant differences in African American older adult 
cognitive status when examined in terms of LASSI-L delayed recall (Table 4-4). A 
criterion for significance of p < .05 was used. On the LASSI-L Delayed Free Recall, CN 
individuals freely recalled more words (M=17.75) than those with aMCI (M=9.70), 
F(1,42)= 21.53, p= .000. The number of intrusions made on LASSI-L Delayed Recall did 







Table 4-4. ANOVA Summary Table for LASSI-L Delayed Recall 
  SS df MS F p 
LASSI-L Delayed Free 
Recall  
     
 Between Groups 706.936 1 706.936 21.536 .000* 
 Within Groups 1378.700 42 32.826   
 Total 2085.636 43    
       
LASSI-L Delayed Free 
Recall Intrusions 
     
 Between Groups 5.603 1 5.603 .774 .384 
 Within Groups 304.033 42 7.239   
 Total 309.636 43    







Research Question 1e. After controlling for covariates, are there differences on 
LASSI-L measures by diagnostic group in African American older adults?  
 An adjusted analysis of covariance was conducted to control for overall 
impairment and literacy level and to determine if after controlling for these covariates, if 
there were differences on LASSI-L measures by diagnostic group in African American 
older adults. A criterion for significance of p < .05 was used. After controlling for 
covariates (Table 4-5), there was only a significant difference on LASSI-L List A Cued 
Recall 2 F (1,37) = 11.24, p = .002 and LASSI-L List B Cued Recall 1 Intrusions 
F(1,37)= 35.70, p =.000 by diagnostic group indicating more impairment for aMCI on 







Table 4-5. Test of Between Subjects Effects (ANCOVA)  
  Type III 
SS 
df MS F p 
LASSI-L List B Cued 
Recall 2 Intrusions 
     
 Corrected Model 18.682 3 6.227 1.487 .234 
 Intercept 17.133 1 17.133 4.092 .050 
 WRAT .424 1 .424 .101 .752 
 MMSE 7.044 1 7.044 1.682 .203 
 AA Group 4.869 1 4.869 1.163 .288 
 Error 154.928 37 4.187   
 Total 519.000 41    
 Corrected Total 173.610 40    
      
LASSI-L List B Cued 
Recall 1 Intrusions 
     
 Corrected Model 153.704 3 51.235 13.281 .000 
 Intercept .856 1 .856 .222 .640 
 WRAT 3.375 1 3.375 .875 .356 
 MMSE .111 1 .111 .029 .866 
 AA Group 137.721 1 137.721 35.700 .000* 
 Error 142.735 37 3.858   
 Total 890.000 41    
 Corrected Total 296.439 40    
 Intercept      
       
LASSI-L List A Cued 
Recall 2 
     
 Corrected Model 64.801 3 21.600 8.306 .000 
 Intercept 7.901 1 7.901 3.038 .090 
 WRAT 1.225 1 1.225 .471 .497 
 MMSE 12.835 1 12.835 4.935 .033 
 AA Group 29.237 1 29.237 11.242 .002* 
 Error 96.224 37 2.601   
 Total 5851.000 41    
 Corrected Total 161.024 40    






Specific Aim 2: To Determine if Performance on the LASSI-L Serves as a Better 
Predator of Diagnostic Group Classification Compared to Other Neuropsychological 
Tests in African American Older Adults 
Before conducting the step-wise logistic regression included in specific aim 2, the 
sample was evaluated to verify that all of the assumptions of logistic regression (i.e. 
binary dependent variable, independent observations, multicollinearity, linearity of 
independent variables to log odds, adequate sample size) were satisfied and all 
assumptions were met.  
Research Question 2a. What is the relationship between scores obtained on the 
LASSI-L and diagnostic group classification in African American Older Adults?  
A step-wise logistic regression was conducted to evaluate the relationship 
between scores obtained on the LASSI-L and diagnostic group classification in African 
American older adults. A criterion for significance of p < .05 was used. Results (Table 4-
6) demonstrated that both the LASSI-L List B Cued Recall 1 intrusions, b = 1.101, Wald 
χ2(1) = 8.04, p = .005, and the LASSI-L Delayed Free Recall b = -.417, Wald χ2(1) = 
8.105, p =.004 significantly predicted whether an individual would be diagnosed as CN 
or aMCI. A combined overall sensitivity of 91.7%, a specificity of 85.0%, and an overall 
classification rate of 88.6% were obtained in distinguishing between individuals who 
were CN and those with aMCI. These high classification rates were obtained despite the 
fact that the LASSI-L was the only neuropsychological measure that was not employed 
as part of the initial diagnostic procedure. 
Areas under the receiver operating characteristic curve (ROC) curve on different 




highest area under the curve was obtained for Cued B1 intrusions with an AUC= .870 
(SE=.054); p<.001. A cut off of 3 by Youden’s criteria yielded a sensitivity of 83.3% and 
a specificity of 77.8%. List B Free Recall intrusions has an AUC of .591 (SE)= (.092) 
which did not reach statistical significance (p=.038). 
Research Question 2b. What is the relationship between scores on traditional 
neuropsychological measures and diagnostic group classification in African American 
Older Adults?  
Since neuropsychological measures such as the HVLT-R, Category Fluency and 
Trails B were part of the initial diagnostic neuropsychological battery, which was 
combined with the clinical diagnosis to assign participants to diagnostic groups, using 
these same measures, particularly the HVLT-R to predict diagnostic group would result 
in potential tautological or circular reasoning. Nonetheless, a step-wise logistic regression 
was conducted to evaluate the relationship between scores obtained on traditional 
neuropsychological measures and diagnostic group classification in African American 
older adults. A criterion for significance of p < .05 was used. Results found that even 
when entering variables such as HVLT, Category Fluency, or Trails B, these variables 
did not significantly improve the model. Moreover, while HVLT delayed recall played a 
large role in determining clinical diagnosis and was individually associated with group 







Table 4-6. Logistic Regression Predicting Diagnostic Group Based on 
LASSI-L Measures 
 B SE Wald df p Odds 
Ratio 
LASSI-L List B Cued 
Recall 1 Intrusions 
1.101 .388 8.044 1 .005* 3.007 
LASSI-L Delayed 
Free Recall 
-.417 .147 8.105 1 .004* .659 
Constant .496 1.519 .107 1 .744 1.642 




Table 4-7. Area Under the ROC Curve 






    Lower 
Bound 
Upper Bound 
LASSI-L List B Free 
Recall Intrusions 
.591 .092 .308 .411 .770 
LASSI-L List B 
Cued Recall 1 
.870 .054 .000* .764 .977 
Table Notes. The test result variable(s): LASSI-L List B Free Recall Intrusions, 
LASSI-L List B Cued Recall 1 has at least one tie between the positive actual state 
group and the negative actual state group. Statistics may be biased 
a. Under the nonparametric assumption 















Specific Aim 3: To Explore How Neuropsychological Measures are Related to 
Volumetric Reductions in AD Prone Regions in African American Older Adults?  
Before conducting the series of Spearman’s rank-order correlation assumption 
analyses including examination of scatterplots for monotonic relationships between 
variables were conducted and all assumptions were met.  
Research Question 3a. Are LASSI-L measures of PSI and frPSI related to MRI 
Volumetric Reductions in left hemisphere AD prone regions? 
A series of Spearman’s rank-order correlations were run to examine if LASSI-L 
measures were related to MRI Volumetric Reductions in left hemisphere hippocampus, 
entorhinal cortex, precuneus, temporal lobe (i.e. superior, middle, inferior), parietal (i.e. 
superior, inferior), and frontal (i.e. superior, rostral orbital). A criterion for significance of 
p < .05 was used. Preliminary results (Table 4-8) demonstrated statistically significant 
correlations between the left superior frontal region and LASSI-L B1 Cued Recall 
Intrusions rs(27)=-.38, p<.05; left rostral orbital frontal and LASSI-L B1 Cued Recall 
Intrusions rs(27)=-.40, p<.05; left rostral orbital frontal and LASSI-L B2 Cued Recall 
Intrusions rs(27)=-.44, p<.05. However, after the Benjamini and Hochberg (1995) 
correction on the Spearman Rank Order Correlation Coefficients for each LASSI-L 







Table 4-8. Relationship between LASSI and Left Hemisphere Volumes in Alzheimer’s Prone Regions (N=29)  
Variables 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
LASSI-L Cued B1 Recall —              
LASSI-L Cued B2 Recall .00** —             
LASSI-L Cued B1 Intrusions .098 .06 —            
LASSI-L Cued B2 Intrusions .023* .00** .0** —           
Left Hippocampus .32 .82 .19 .80 —          
Left Entorhinal Cortex .61 .31 .75 .70 .081 —         
Left Precuneus .96 .67 .96 .61 .043* .61 —        
Left Superior Temporal .95 .56 .47 .39 .041* .28 .06 —       
Left Middle Temporal .59 .97 .38 .92 .00** .64 .00** .00** —      
Left Inferior Temporal .64 .76 .10 .28 .047* .03* .03* .045 .00** —     
Left Superior Parietal .68 .73 .25 .51 .00** .15 .00** .089 .00** .00** —    
Left Inferior Parietal .23 .89 .62 .87 .10 .28 .00** .00** .00** .01** .02* —   
Left Superior Frontal .80 .96 .04* .54 .001 .02* .00** .017* .00** .00** .00** .00** —  
Left Rostral Orbital Frontal .29 .30 .03* .02* .02 .42 .019* .021* .26 .047* .00** .022* .00** — 
Table Notes. Due to the violation of normality assumptions, non-parametric Spearman Rank Order Correlation  











Research Question 3b. Are Traditional Neuropsychological Measures related to 
MRI Volumetric Reductions in left hemisphere AD prone regions? 
A series of Spearman’s rank-order correlations were run to examine if traditional 
neuropsychological measures (i.e. HVLT Total, HVLT delay, Trails B, category fluency) 
were related to MRI Volumetric Reductions in left hemisphere hippocampus, entorhinal 
cortex, precuneus, temporal lobe (i.e. superior, middle, inferior), parietal (i.e. superior, 
inferior), and frontal (i.e. superior, rostral orbital). A criterion for significance of p < .05 
was used. A criterion for significance of p < .05 was used. The Benjamini and Hochberg 
(1995) correction was employed on the Spearman Rank Order Correlation Coefficients 
for each traditional measure (correcting for 10 MRI measures), which yielded no 






Table 4-9. Relationship between Traditional Measures and Left Hemisphere Volumes in Alzheimer’s Prone Regions (N=29)  
Variables 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
HVLT-R Total —              
HVLT-R Delay .00** —             
Trails B Total .00** .00** —            
Category Fluency .01** .028* .00** —           
Left Hippocampus .07 .24 .34 .36 —          
Left Entorhinal Cortex .17 .41 .45 .40 .082 —         
Left Precuneus .43 .24 .39 .15 .008** .03* —        
Left Superior Temporal .19 .09 .41 .39 .009** .11 .03* —       
Left Middle Temporal .44 .12 .42 .09 .00** .44 .00** .00** —      
Left Inferior Temporal .17 .08 .07 .19 .00** .06 .012* .059 .00** —     
Left Superior Parietal .36 .36 .31 .45 .00** .11 .00** .018* .00** .00** —    
Left Inferior Parietal .41 .41 .45 .18 .012* .11 .00** .00** .00** .00** .00** —   
Left Superior Frontal .20 .20 .40 .36 .001** .03* .00** .00** .00** .00** .00** .00** —  
Left Rostral Orbital Frontal .23 .23 .36 .36 .00** .17 .00** .00** .017* .037* .00** .00** .00** — 




Chapter 5: Discussion 
 
 Given the paucity of research in the area, the purpose of the current dissertation 
study is to extend the body of research on effective early detection of Alzheimer’s disease 
(AD) in African Americans. There were three primary aims of the current investigation: 
(1) Explore whether there were differences in performance on the LASSI-L between 
amnestic-mild cognitively impaired (aMCI) and cognitively normal (CN) African 
American older adults, (2) to determine if performance on the LASSI-L serves as a better 
predictor of diagnostic group classification compared to other neuropsychological tests in 
African American older adults, and (3) Explore how neuropsychological measures are 
related to volumetric reductions in AD prone regions in African American older adults.  
Primary Outcomes 
The first aim of the current study was to explore whether there were differences in 
performance on the LASSI-L between aMCI and CN African American older adults. 
Specifically, it was predicted that measures sensitive to initial learning and storage,  
proactive semantic interference (PSI), failure to recover from proactive semantic 
interference (frPSI) and retroactive semantic interference (RSI) would be more impacted 
in AA CN versus their aMCI counterparts. Results supported the hypothesis of difference 
in performance on LASSI-L measures between diagnosis groups, as those who were 
cognitively normal were better able to learn, encode, and store to-be-remembered 
information and less susceptible to interference, than those with aMCI. First, with regards 
to initial learning and storage of information as measured by List A Free and Cued Recall 
1 and 2, those who were cognitively normal were able to recall more words and make 




CN were better able to learn, encode, and store to-be-remembered information than those 
with aMCI. Second, after this initial learning and storage of List A, participants were 
asked to learn a second semantically related list of words (List B). The first presentation 
of List B assesses for PSI as measured by List B Free and Cued Recall 1. Results found 
that cognitively normal individuals remembered more words and made fewer intrusion 
errors. These findings indicate that those with aMCI were more susceptible to the effects 
of PSI than those who are cognitively normal. Participants were then shown List B again 
to provide them with the opportunity to recover from these PSI effects. When examining 
participants’ ability or failure to recover from PSI as measured by List B Cued Recall 2, 
results found that cognitively normal individuals were able to recall more words than 
those with aMCI. These results indicate that individuals with aMCI are more likely to fail 
to recover from PSI compared to their cognitively normal counterparts. After the second 
presentations of List B, participants were asked to recall words from the original list (List 
A) to assess for RSI. Results indicated that cognitively normal individuals were able to 
recall more words from the original list during free recall compared to those with aMCI. 
This finding suggests that those with aMCI were more susceptible to the effects of RSI. 
Delayed recall of both Lists A and B were assessed after 20-minute delay. Results 
indicated that cognitively normal individuals were able to recall more words on delayed 
recall compared to aMCI. Taken together these results supported the hypothesis that 
African Americans diagnosed with aMCI were more impaired in their ability to learn and 
remember new information and further, that they were negatively impacted by the effects 
of PSI and RSI. Furthermore, these results suggest that those with aMCI failed to recover 




Given these documented differences on LASSI-L performance occurred within an 
older African American sample, additional analyses were conducted in order to account 
for known covariates, such as literacy and global cognition. Specifically, several studies 
have cited the impact that literacy, as measured by word reading, can have on 
neuropsychological test performance. For instance, studies show that African Americans 
obtain significantly lower scores than Caucasians on measures of word list learning and 
memory, figure memory, abstract reasoning, fluency, and visuospatial skills, but that 
these racial differences become nonsignificant when adjusting for literacy (Manly, 
Touradji, Tang, & Stern, 2003). Literacy has been found to be the most influential 
predictor of cognitive test performance, even after accounting for age, sex, years, of 
education, and acculturation level and is thus believed to be a better indicator of cognitive 
reserve (Manly, Byrd, & Touradji, 2004). A longitudinal study examining cognitive 
decline across racial groups found that older adults with both high and low levels of 
literacy decline in immediate and delayed memory over time, but that this decline is more 
rapid for low literacy older adults (Manly, Touradji, Tang, & Stern, 2003).  
Because of previous research demonstrating the impact that literacy and cognitive 
reserve may have on neuropsychological test performance, further analysis was 
conducted to control for these effects might have on LASSI-L performance. After 
controlling for these variables using the MMSE and WRAT-4 word reading, cognitively 
normal and aMCI only differed on their second cued recall of list A and List B cued 
recall 1 number of intrusions. These results indicate that those with aMCI exhibit more 
impairment in their initial learning and storage of information and suffer from PSI due to 




These results are consistent with previous research on Hispanic and non-Hispanic 
individuals which found that those with aMCI had greater difficulty with initial learning 
and storage and were more susceptible to PSI compared to those who were cognitively 
normal (Crocco et al., 2013; Loewenstein et al., 2016). Given that previous studies have 
demonstrated that PSI is one of the strongest predictors of progression from aMCI to 
dementia and that cued recall deficits are a more sensitive marker of AD pathology than 
free recall, the use of the LASSI-L to identify these deficits may prove valuable in 
identifying those individuals who are at risk of further decline (Curiel et al., 2013; 
Loewenstein et al., 2016).  
Diagnostic Accuracy 
The second aim of this study was to determine if performance on the LASSI-L 
served as a better predictor of diagnostic group classification compared to other 
neuropsychological tests in African American older adults. The obtained findings 
indicate that two measures on the LASSI-L (List B Cued Recall 1 intrusions and Delayed 
Free Recall) significantly predicted whether an individual would be diagnosed as 
cognitively normal or with aMCI. These measures demonstrated a combined overall 
sensitivity of 91.7% and a specificity of 85.0%, and a classification rate of 88.6% in 
distinguishing between individuals who were cognitively normal and those with aMCI.  
Since neuropsychological measures such as the HVLT-R, Category Fluency and 
Trails B were part of the initial diagnostic neuropsychological battery, which was 
combined with the clinical diagnosis to assign participants to diagnostic groups, using 
these same measures, particularly the HVLT-R to predict diagnostic group would result 




completely independent of initial diagnostic formulation. Nonetheless, we conducted 
post-hoc analyses entering Trails B, LASSI-L and Category Fluency into logistic 
regression models and only LASSI-L List B Cued Recall 1 intrusions and LASSI-L 
delayed recall entered into the model. ROC curve analysis demonstrated greatest 
sensitivity (83.3%) and specificity (77.8%) using LASSI-L List B Cued Recall 1 
intrusions when using a cut off of 3.  
Taken together, these results indicate that for African American older adults,  
PSI and delayed recall and measured by the LASSI-L are important diagnostic indicators 
above and beyond traditional neuropsychological assessments. As such, utilizing the 
LASSI-L to assess for PSI and delayed recall may provide high diagnostic accuracy for 
this population earlier in the disease state than measures currently utilized. These results 
are consistent with previous studies that have demonstrated the LASSI-L’s ability to 
differentiate between cognitively normal individuals and those ranging in severity of 
impairment in Hispanic and predominately White individuals (Curiel et al., 2013; 
Loewenstein et al., 2016). Similarly, these results align with previous studies that 
demonstrate that the LASSI-L evidences higher classification rates than those obtained 
by other traditional neuropsychological assessment measures among predominately 
White individuals (Curiel et al., 2013; Crocco, Curiel, Acevedo, Czaja, & Loewenstein, 
2014).  
Magnetic Resonance Imaging (MRI) 
The third aim of this study was to explore how neuropsychological measures are 
related to volumetric reductions in AD prone regions in African American older adults. 




This is inconsistent with previous research where the LASSI-L measures related to PSI 
and frPSI were found to uniquely correlate to volumetric reductions on MRI within 
medial temporal lobes (e.g. entorhinal cortex) and other AD prone regions (e.g. 
precuneus, superior frontal and superior parietal regions) (Loewenstein et al., 2017; 
Crocco et al., 2013; Curiel et al., 2013). There are a number of possible explanations for 
the lack of significant MRI findings. First, despite including the entire sample (both CN 
and aMCI), which is consistent with prior studies, the sample size available for MRI 
scans was modest and did not provide enough statistical power to yield significant results.  
Secondly, given the population of interest, community based African Americans; the 
participants may have had underlying conditions other than AD to a greater extent than 
the samples utilized in previous studies (i.e. Hispanic and predominately White 
individuals) (Brooks & Loewenstein, 2010).  To this point, many participants evidenced 
cardiovascular risk factors such as hypertension, diabetes, hypercholesterolemia, and 
history of stroke (Table 5-1). These risk factors, as well as the high rates of past drug use 
typically seen in African American Baby Boomers (Pope, Wallhagen, & Davis, 2010) 
may indicate that the memory loss observed in this sample may more accurately be 
classified as mixed etiology. As such, future studies should seek to recruit a larger sample 
without major health conditions known to impact cognition. In addition, future studies 
may benefit from the use of PET amyloid scans and/or tau imaging to determine if other 







Table 5-1. Cardiovascular Risk Factors.4 





Hypertension 68.8% 52.4% .45 .51 
Diabetes 23.5% 19.0% .00 1.00 
Hypercholestrolemia 31.3% 23.8% .02 .80 
Stroke 11.8% 4.8% .04 .85 
 
  
                                                 





 The current dissertation study has several strengths, including those related to 
design characteristics. Specifically the current study utilized a detailed, well-established 
and standardized criteria for the evaluation and diagnosis of both CN and aMCI patients, 
as well as, expert readings of volumetric magnetic resonance imaging data for 
participants, and the analyses included false discovery rates to control for false errors 
(Benjamini & Hochberg, 1995). Additionally, this dissertation study adds to the present 
literature base by examining LASSI-L. performance in African Americans, which are an 
underserved and underrepresented population in clinical research. This is significant as 
prevalence and incidence rates of dementia diagnoses across racial and ethnic groups 
have found that the rates of dementia among African Americans far outnumber that of 
other racial and ethnic groups (Mehta & Yeo, 2017). Furthermore, the current study is 
one of the first to determine the extent to which proactive, retroactive, and failure to 
recover from proactive semantic interference on a novel cognitive stress test could 
differentiate between aMCI and cognitively normal African American older adults.  
Limitations 
While the current study had several strengths, a number of limitations are worth 
noting. First, one important limitation of the current study is that of the forty-four total 
participants (24 of these participants were diagnosed as cognitively normal and 20 were 
diagnosed as having mild cognitive impairment) only 29 of these individuals underwent 
MRI scans and, as such, normal and MCI participants were combined. Additional 
participants would have increased the power of statistical tests, allowed for additional 




validity.  However, recruitment of African American participants is complicated by a 
number of factors including mistrust of health care providers and researchers, as well as 
personal and historic discrimination (Mahoney et al., 2005). In fact, many African 
Americans report being unwilling to participate in research due to historic research 
instances such as the Tuskegee Study of Untreated Syphilis (Green et al., 1997). Personal 
discrimination, particularly in the Southern United States where this study was 
conducted, may also have added to this sense of mistrust in potential participants 
(Mahoney et al., 2005). Additionally, this study involved the recruitment of participants 
belonging to the Baby Boom cohort (i.e. those born between mid-1946 and mid-1964) 
who have been found to be more pessimistic regarding individuals in lower social status 
or those viewed as less fortunate (Riggs & Turner, 2000; Hogan, Perez, & Bell, 2008). 
Because this study consists largely of African American participants who were recruited 
from local churches, the sample is likely skewed and represents unique variance not 
accounted for by this study.  
Second, despite comprehensive screening with the NPI to exclude participants 
meeting full criteria for a Major Mood Disorder from the study, there is a possibility that 
some participants may have experienced a sub-syndromal mood disorder that could have 
affected cognitive performance. We believe that this is unlikely as previous research has 
shown no evidence between mild mood symptoms and performance on the LASSI-L 
(Crocco et al., 2018) however future research is needed in order to confirm these 
findings. 
Third, the fact that the LASSI-L’s diagnostic accuracy was compared to memory 




though the LASSI-L still compared favorably, future studies would benefit from the 
comparison of the LASSI-L and neuropsychological measures, which were not used in 
the diagnostic process.  
Finally, it is possible that this community dwelling AA population did not have 
underlying AD pathology but instead were experiencing cognitive symptoms due to other 
etiologies. As such, future research should seek to recruit participants with fewer 
cardiovascular risk factors. 
Future Directions  
 Future studies should continue to investigate the performance of African 
Americans, with varying severity of impairment, on the LASSI-L. Recruiting a larger 
sample of participants would help future investigators better evaluate the LASSI-L’s 
diagnostic features and accuracy among this population. Future studies should attempt to 
recruit a more diverse sample (e.g. different geographic regions, recruitment settings). 
Due to high levels of health risk factors observed in this sample, future studies should 
also attempt to recruit participants with family histories of AD, identified with amyloid 
and tau pathology by PET scan imaging, as well as, focus on individuals with both high 
and low levels of cardiovascular risk factors so as to better isolate a purely AD pathology. 
Because literacy has been linked to neuropsychological test performance and rates of 
cognitive decline over time, future studies should account for literacy levels to examine 
the effects it may have on performance, particularly in minority populations. Finally, 
future studies should include the comparison of the LASSI-L’s diagnostic accuracy to the 
diagnostic accuracy rates of other independent neuropsychological measures for African 





 In conclusion, the majority of the results of this dissertation are consistent with 
the prior literature in that there are differences in performance on the LASSI-L between 
diagnostic groups and the LASSI-L was able to differentiate between those diagnosed 
with aMCI and those who are cognitively normal with high-observed specificity and 
sensitivity. Specifically, the current dissertation found that those with aMCI have greater 
difficulty with initial learning and storage of information and are more susceptible to PSI 
and some aspects of frPSI and RSI compared to those who were cognitively normal. 
However, after controlling for global cognition and literacy, only aspects of PSI and RSI 
remained predictive.  Furthermore, inconsistent with the prior literature, the current study 
did not find LASSI-L measures related to volumetric reductions in AD prone brain 
regions. This inconsistency may be due to a modest sample size and/or, given the high 
rates of cardiovascular risk factors within the sample, the observed memory loss may 
have been caused by other etiologies. Despite this inconsistency, demographic trends and 
projected prevalence rates of AD within African Americans (Celsis, 2000; Sherwin, 
2000), coupled with the fact that emerging dementias therapies are more effective in the 
earlier stages, establish an increasing need for early detection of AD in susceptible 
populations (Loewenstein, Curiel, Duara, & Buschke, 2017). As such, cognitive stress 
tests such as the Loewenstein-Acevedo Scale of Semantic Interference and Learning 
(LASSI-L), can provide quick, accurate, and inexpensive diagnostic classification across 
impairment severity (Loewenstein, Curiel, Duara, & Buschke, 2017) and, as shown in 
this dissertation, across racial groups. Overall, the current study, in line with previous 
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Diagnostic Statistical Manual of Mental Disorders 5th Edition Diagnosis of Alzheimer's 



























Major or Mild Neurocognitive Disorder Due to Alzheimer’s Disease 
A. The criteria are met for major or mild neurocognitive disorder. 
B. There is insidious onset and gradual progression of impairment in one or more 
cognitive domains (for major neurocognitive disorder, at least two domains must 
be impaired). 
C. Criteria are met for either probable or possible Alzheimer’s disease as follows:  
 
For major neurocognitive disorder:  
Probable Alzheimer’s disease is diagnosed if either of the following is 
present; otherwise, possible Alzheimer’s disease should be diagnosed.  
(1) Evidence of a causative Alzheimer’s disease genetic mutation from family 
history or genetic testing.  
(2) All three of the following are present: 
a) Clear evidence of decline in memory and learning and at least one other 
cognitive domain (based on detailed history or serial neuropsychological 
testing). 
b) Steadily progressive, gradual decline in cognition, without extended 
plateaus. 
c) No evidence of mixed etiology (i.e., absence of other neurodegenerative or 
cerebrovascular disease, or another neurological, mental, or systemic 
disease or condition likely contributing to cognitive decline). 
 
For mild neurocognitive disorder:  
Probable Alzheimer’s disease is diagnosed if there is evidence of a causative 
Alzheimer’s disease genetic mutation from either genetic testing or family 
history.  
Possible Alzheimer’s disease is diagnosed if there is no evidence of a 
causative Alzheimer’s disease genetic mutation from either genetic testing or 
family history, and all three of the following are present:  
1) Clear evidence of decline in memory and learning. 
2) Steadily progressive, gradual decline in cognition, without extended 
plateaus. 
3) No evidence of mixed etiology (i.e., absence of other neurodegenerative or 
cerebrovascular disease, or another neurological or systemic disease or 
condition likely contributing to cognitive decline). 
 
D. The disturbance is not better explained by cerebrovascular disease, another 
neurodegenerative disease, the effects of a substance, or another mental, 
neurological, or systemic disorder. 
American Psychiatric Association. (2013). Diagnostic and statistical manual of mental 






















































F00 Dementia in Alzheimer’s disease 
 
The following features are essential for a definite diagnosis: 
 
A. Presence of a dementia as described above. 
B. Insidious onset with slow deterioration. While the onset usually seems difficult to 
pinpoint in time, realization by others that the defects exist may come suddenly. 
An apparent plateau may occur in the progression. 
C. Absence of clinical evidence, or findings from special investigations, to suggest 
that the mental state may be due to other systemic or brain disease which can 
induce a dementia (e.g. hypothyroidism, hypercalcaemia, vitamin B12 deficiency, 
niacin deficiency, neurosyphilis, normal pressure hydrocephalus, or subdural 
hematoma). 
D. Absence of a sudden, apoplectic onset, or of neurological signs of focal damage 
such as hemiparesis, sensory loss, visual field defects, and incoordination 
occurring early in the illness (although these phenomena may be superimposed 
later). 
 
In a certain proportion of cases, the features of Alzheimer's disease and vascular 
dementia may both be present. In such cases, double diagnosis (and coding) 
should be made. When the vascular dementia precedes the Alzheimer's disease, it 
may be impossible to diagnose the latter on clinical grounds. 
 
Includes: primary degenerative dementia of the Alzheimer's type 
 
Differential diagnosis. Consider: a depressive disorder (F30-F39); delirium 
(F05.-); organic amnesic syndrome (F04); other primary dementias, such as in 
Pick's, Creutzfeldt-Jakob or Huntington's disease (F02.-); secondary dementias 
associated with a variety of physical diseases, toxic states, etc. (F02.8); mild, 
moderate or severe mental retardation (F70-F72). 
 
Dementia in Alzheimer's disease may coexist with vascular dementia (to be coded 
F00.2), as when cerebrovascular episodes (multi-infarct phenomena) are 
superimposed on a clinical picture and history suggesting Alzheimer's disease. 
Such episodes may result in sudden exacerbations of the manifestations of 
dementia. According to postmortem findings, both types may coexist in as many 













F00.0 Dementia in Alzheimer's disease with early onset 
 
Dementia in Alzheimer's disease beginning before the age of 65. There is 
relatively rapid deterioration, with marked multiple disorders of the higher 
cortical functions. Aphasia, agraphia, alexia, and apraxia occur relatively early in 
the course of the dementia in most cases. 
 
Diagnostic Criteria: As for dementia, described above, with onset before the age 
of 65 years, and usually with rapid progression of symptoms. Family history of 
Alzheimer's disease is a contributory but not necessary factor for the diagnosis, as 
is a family history of Down's syndrome or of lymphoma. 
 
Includes: Alzheimer's disease, type 2 presenile dementia, Alzheimer's type 
 
F00.1 Dementia in Alzheimer's disease with late onset 
 
Dementia in Alzheimer's disease where the clinically observable onset is after the 
age of 65 years and usually in the late 70s or thereafter, with a slow progression, 
and usually with memory impairment as the principal feature. 
 
Diagnostic guidelines: As for dementia, described above, with attention to the 
presence or absence of features differentiating the disorder from the early-onset 
subtype (F00.0). 
 
Includes: Alzheimer's disease, type 1 senile dementia, Alzheimer's type 
 
World Health Organization. (1993). The ICD-10 classification of mental and behavioural 


















National Institute of Neurological and Communicative Disorders and Stroke (Nincds) of 
The United States and The Alzheimer’s Disease and Related Disorders 

























I. The criteria for the clinical diagnosis of PROBABLE Alzheimer’s disease include: 
— dementia established by clinical examination and documented by the Mini-
Mental Test, Blessed Dementia Scale, or some similar examination, and confirmed 
by neuropsychological tests; 
— deficits in two or more areas of cognition; 
— progressive worsening of memory and other cognitive functions; 
— no disturbance of consciousness; 
— onset between ages 40 and 90, most often after age 65; and 
— absence of systemic disorders or other brain diseases that in and of themselves 
could account for the progressive deficits in memory and cognition. 
II. The diagnosis of PROBABLE Alzheimer’s disease is supported by: 
— progressive deterioration of specific cognitive functions such as language 
(aphasia), motor skills (apraxia), and perception (agnosia); 
— impaired of activities of daily living and altered patterns of behavior; 
— family history of similar disorders, particularly if confirmed 
neuropathologically; and 
— laboratory result of: 
— normal lumbar puncture as evaluated by standard techniques, 
— normal pattern or nonspecific changes in EEG, such as increased slow-wave 
activity, and 
— evidence of cerebral atrophy on CT with progression documented by serial 
observation. 
III. Other clinical features consistent with the diagnosis of PROBABLE Alzheimer’s 
disease, after exclusion of causes of dementia other than Alzheimer’s disease, include: 
— plateaus in the course of progression of the illness; 
— associated symptoms of depression, insomnia, incontinence, delusions, illusions, 
hallucinations, catastrophic verbal, emotional, or physical outbursts, sexual 
disorders, and weight loss; 
— other neurologic abnormalities in some patients, especially with more advanced 
disease and including motor signs such as increased muscle tone, myoclonus, or 
gait disorder; 
— seizures in advanced disease; and 
— CT normal for age. 
IV. Features that make a diagnosis of PROBABLE Alzheimer’s disease uncertain or 
unlikely include: 
— sudden, apoplectic onset; 
— focal neurologic findings such as hemiparesis, sensory loss, visual field deficits, 
and incoordination early in the course of the illness; and 
— seizures or gait disturbances at the onset or very early in the course of the 
illness. 
V. Clinical diagnosis of POSSIBLE Alzheimer’s disease: 
— may be made on the basis of the dementia syndrome, in the absence of other 
neurologic, psychiatric, or systemic disorders sufficient to cause dementia, and in 
the presence of variations in the onset, in the presentation, or in the clinical course; 
— may be made in the presence of a second systemic or brain disorder sufficient to 




— should be used in research studies when a single, gradually progressive severe 
cognitive deficit is identified in the absence of other identifiable cause. 
VI. Criteria for diagnosis of DEFINITE Alzheimer’s disease are:  
— the clinical criteria for probable Alzheimer’s disease; and  
— histopathologic evidence obtained from a biopsy or autopsy. 
VII. Classification of Alzheimer’s disease for research purposes should specify features 
that may differentiate subtypes of the disorder, such as: 
— familial occurrence; 
— onset before age of 65; 
— presence of trisomy-21; and 
— coexistence of other relevant conditions such as Parkinson’s disease. 
 
McKhann, G., Drachman, D., Folstein, M.,  Katzman, R., Price, D., & Stadlan, M. E. 
(1984). Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA work 
group* under the auspices of department of health and human services task force on 







Loewenstein-Acevedo Scales of Semantic Interference and Learning (LASSI-L) 
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